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A Comprehensive Report on Marijuana: Focus on the Paso Del Norte Region
The aim of the current review is to examine the evidence surrounding the therapeutic
effects and health consequences associated with marijuana use. Repercussions that have
emerged as a result of marijuana legalization in the U.S. are identified, including the impact of
legalization on the healthcare system, motor vehicle accidents, and crime. Furthermore, the
current review examines literature related to marijuana and tobacco use in order to differentiate
the health effects of each substance. Lastly, the authors of the current review discuss the impact
of marijuana in communities in the Paso Del Norte Region.
Brief History
The earliest record of medicinal cannabis use dates back to 4,000 B.C. in China where it
was used as an anesthetic during surgical operations (Drug Policy Alliance, 2016a). Records
from 1,000 B.C. indicate that cannabis was used medicinally in India to treat anxiety (Drug
Policy Alliance, 2016a). In the 15th century, China listed cannabis as a painkiller in the world’s
oldest pharmacopeia, the pen-ts'ao ching (Zuardi, 2006). Records from Germany during the
medieval times suggest that cannabis was used as an anesthetic for childbirth and toothaches
(Drug Policy Alliance, 2016a). By the 19th century, Europe and America published over 100
scientific articles regarding the therapeutic effects of cannabis (Zuardi, 2006). In the 1840s, a
French doctor by the name of Jacques-Joseph Moreau began experimenting with the intoxicating
properties of cannabis and suggested that cannabis was effective as a sleeping aid, effective for
increasing appetite, and effective for suppressing headaches (Pisanti & Bifulco, 2017).
Throughout the 19th century cannabis extracts were widely marketed (Savage et al., 2016).
Furthermore, cannabis was added to the U.S. Pharmacopeia in 1850 as a treatment for a number
of afflictions including mitigating pain and increasing appetite (Savage et al., 2016). Despite the
5

evidence highlighting the therapeutic properties of cannabis, congress passed the Marijuana Tax
Act in 1937, beginning the federal prohibition of cannabis (Musto, 1972). The U.S.
Pharmacopeia subsequently removed cannabis as a medicinal treatment in 1941 (Zuardi, 2006).
Under President Richard Nixon in 1970, marijuana was categorized as a Schedule I drug,
declaring that marijuana has high potential for physical and psychological abuse, and does not
contain medicinal properties (Bilz, 1992). Cannabis has now been categorized as a Schedule I
drug for over half a century.
Why Marijuana Was Made Illegal in the U.S. The most commonly cited explanation is
related to Mexican immigration following the Mexican Revolution (Pagano, 2018; Ferraiolo,
2007; Musto, 1991). For example, in a Google search using the following search terms: “why
was marijuana made illegal in the U.S.”, nearly every article that populates refers to marijuana
being banned due to the prejudices associated with Mexican immigrants and their drug of choice
(i.e., marijuana). Discussions of marijuana being banned due to prejudices associated with
Mexican immigration are also commonly discussed in peer reviewed journals. In a manuscript
published in the Journal of Policy History titled, “From killer weed to popular medicine: The
evolution of American drug control policy, 1937–2000”, the author writes,
“Domestic concern about marijuana originated in the Southwest, an area that saw an
influx of Mexican immigrant laborers in the 1920s. Mexicans were thought to be prone to
criminal and deviant behavior; during the Great Depression they became an unwelcome
population and Southwestern states complained to the federal government about their marijuana
use. In the early 1920s, New Orleans police claimed that marijuana use was responsible for a
large number of crimes, particularly among the city’s black population. The association
between marijuana and politically marginal groups stirred fear about the drug’s effects, helped
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to justify its regulation, and ultimately led to a “latent social consensus” that supported
marijuana laws for several decades.” (Ferraiolo, 2007, p. 156).
Scientific American journal and magazine published an article stating,
“The practice of smoking cannabis leaves came to the U.S. with Mexican immigrants,
who had come North during the 1920s to work and it soon extended to white and black jazz
musicians. As the Great Depression of the 1930s settled over America, the immigrants became
an unwelcome minority linked with violence and with growing and smoking marijuana. Western
states pressured the federal government to control marijuana use. The first official response was
to urge adoption of a uniform state antinarcotics law” (Musto, 1991, p. 9).
Interestingly, marijuana was classified as a Schedule I drug for similar reasons. For
example, John Ehrlichman, a top aide for President Nixon explained why marijuana was listed as
a Schedule I drug, stating,
“You want to know what this was really all about? The Nixon campaign in 1968, and the
Nixon White House after that, had two enemies: the antiwar left and black people. You
understand what I’m saying? We knew we couldn’t make it illegal to be either against the war or
black, but by getting the public to associate the hippies with marijuana and blacks with heroin,
and then criminalizing both heavily, we could disrupt those communities. We could arrest their
leaders, raid their homes, break up their meetings and vilify them night after night on the
evening news. Did we know we were lying about the drugs? Of course we did” (Downs, 2016).
Overall, there are other explanations for why marijuana was made illegal that have been
documented. For example, one reason is that the paper pulp industry was booming as a result of
the newspaper industry, thus, investors in the paper pulp industry were worried that hemp (a
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product of cannabis), would replace paper pulp. However, reasons for banning marijuana aside
from the prejudices associated with minorities are less discussed within the literature.
Current U.S. Legislation. Within the last two decades, more than half of the states in the
U.S. have legalized medicinal marijuana use. Additionally, ten states (Alaska, California,
Colorado, Maine, Massachusetts, Michigan, Nevada, Oregon, Vermont, and Washington,) and
the District of Columbia have legalized recreational marijuana use for individuals who are 21
years of age or older (see Table 1). Despite the trend of marijuana legalization in many states,
marijuana is categorized as a Schedule I drug on the federal level (declaring no medicinal
benefits) and thus there are many barriers to researching marijuana. Arguably, lengthy statutory
and regulatory processes imposed by the government have systematically impeded rigorous
research on marijuana (Bostwick, 2012; Taylor, 2008). Investigators interested in conducting
research on marijuana must undertake one of the most stringent review processes. This involves
submitting an investigational new drug (IND) application to the U.S. Food and Drug
Administration (FDA), contacting the National Institute on Drug Abuse (NIDA) to obtain an
administrative letter of authorization (LOA), and applying for licensure to possess marijuana to
the U.S. Drug Enforcement Administration (DEA) (NASEM, 2017). Dr. Orrin Devinsky is the
director of the Comprehensive Epilepsy Center at New York University’s Langone Health and
has received approval from the FDA to investigate the use of marijuana for treating epilepsy. In
an interview with Time Magazine, Dr. Devinsky describes his experience of receiving approval,
“The DEA sent men with guns to my office to inspect” (Sifferlin, 2018). Dr. Devinksy goes on
to explain that the DEA required the hospital to have a special alarm system to secure the
marijuana, a special lock on the door of the room in which the marijuana was stored, and a safe
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large enough that it required engineers to visit the room and ensure that the safe did not exceed
the maximum weight capacity for the upper floor level in which it was stored (Sifferlin, 2018).
Importantly, on March 23, 2018, President Donald Trump signed the Consolidated
Appropriations Act of 2018. This act protects medical cannabis patients and businesses in 46
states from federal intervention; the act does not include Idaho, Kansas, Nebraska, or South
Dakota (H.R.1625, 2018). Presumably, Senators or Representatives in the latter states requested
to not be included on the list. In May 2018, the VA Medicinal Cannabis Research Act of 2018
was passed and demands the Department of Veteran Affairs (VA) to conduct research on the
effectiveness of medical marijuana for treating various afflictions (i.e., post-traumatic stress
disorder and pain) in veterans enrolled in the VA health care system (H.R.5520, 2018). The
latter act seemingly represents a shift in opinions about medical marijuana within the U.S.
government. Specifically, receiving approval to conduct research on marijuana has been
particularly difficult due to its classification as a Schedule I drug, thus, passing an act that
demands research on marijuana is atypical.
Current Legislation in Bordering Countries. In the last decade, marijuana legislation has
changed its status in countries bordering the U.S. For example, Mexico decriminalized the
possession of small amounts of marijuana (i.e., less than 5 grams of dried marijuana) in 2009
with aims of reallocating law enforcement resources toward big-time dealers instead of minor
consumers (Wilkinson & Marosi, 2009). Additionally, Mexico legalized non-psychoactive
cannabis-based substances for medicinal purposes in 2017 (Osborne, 2017). Canada legalized
recreational marijuana use nationwide on October 17th, 2018 (Gillies, 2018). Canada legalized
recreational marijuana to eliminate illegal sales and create a profitable market (Team, 2018).
The Prime Minister Justin Trudeau justified the legislation by stating the following, “It’s been
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too easy for our kids to get marijuana – and for criminals to reap the profits… today we change
that. Our plan to legalize and regulate marijuana just passed the Senate” (Berke, 2018). Canada
is predicting that the marijuana market will be a $65 billion industry by 2020 (Berke, 2018).
Canadians over the age of 18 will be able to purchase marijuana from federally licensed
producers, grow up to four plants at home, and possess up to 30 grams of dried cannabis (Sapra,
2018). Provinces within Canada are allowed to set their own rules for how marijuana is sold
(i.e., minimum age to consume marijuana or locations that are permitted to consume marijuana),
however, the federal government has imposed guidelines that all provinces must abide by
(Gillies, 2018). For example, packaging of marijuana products must be plain and must include
strict health warning labels (BBC, 2018). Furthermore, the federal government imposed the
following restrictions on advertisements: 1) promotions toward youth, 2) promotions depicting
celebrities, and 3) promotions depicting characters or animals (BBC, 2018). Research suggests
that tobacco advertisements are effective at increasing tobacco use in the youth (Henriksen,
Flora, Feighery, & Fortmann, 2002; Moodie, MacKintosh, Brown, & Hastings, 2008), thus the
intent of imposing restrictions on marijuana advertisements is to similarly prevent increases in
marijuana use in the youth. The ease of access initiated by the legalization of marijuana in the
majority of the U.S. and bordering countries may lead to a surge in marijuana use in the U.S.
resulting in unexpected health consequences.
Current Prevalence of Marijuana Use in the U.S. The rates of marijuana use in the US
have increased considerably over the last decade. Approximately five million people reported
using marijuana daily in 2007 (Substance Abuse and Mental Health Services Administration
[SAMHSA], 2014) and approximately eight million people reported using marijuana daily in
2013 (SAMHSA, 2014). In 2015, approximately 19.8 million (7.5%) Americans over the age of
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12 reported using marijuana in the past month (Azofeifa, 2016). A recent poll estimated that
approximately 35 million Americans are “regular marijuana users,” defined as using marijuana at
least one to two times a month (Marist Poll, 2017).
Despite the legal age of consuming marijuana being set to a minimum of 21 in many of
the states within the U.S., the rates of marijuana use in youth attending U.S. high schools is
alarming. The 2017 Monitoring the Future (MTF) survey conducted at the Survey Research
Center in the Institute for Social Research at the University of Michigan. The MTF is a
nationally representative survey that assesses the prevalence of licit and illicit drug use in 8th
graders (N = 16,010), 10th graders (N = 14,171), and 12th graders (N = 13,522) (Johnston et al.,
2018). MTF defines prevalence of drug use as the proportion of a population or subpopulation
who have used a drug over a particular period of time. The 2017 MTF survey reported that
marijuana is the most widely used illicit drug in youth. The prevalence of 12th, 10th, and 8th
graders who have used marijuana in their lifetime is approximately 45%, 31%, and 14%,
respectively. The former result suggests that nearly one out of every two students in high school
will try marijuana by the time they graduate. Daily marijuana use (as indexed by using
marijuana 20 or more times in the past 30 days) in 12th, 10th, and 8th graders was approximately
5.9%, 2.9%, and 0.8%, respectively. Furthermore, 71% of high school seniors reported that they
do not view marijuana as harmful. Attitudes and opinions about marijuana legalization are not
only improving in the youth, but seem to be improving in adults across the U.S.
Approximately 12% of Americans believed that marijuana should be legalized in 1969,
approximately 31% of Americans believed that marijuana should be legalized in 2000,
approximately 52% of Americans believed marijuana should be legalized in 2014, approximately
57% of Americans believed marijuana should be legalized in 2016, and approximately 61% of
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Americans believed marijuana should be legalized in 2017 (Geiger, 2018; Ingraham, 2017).
Considering the current rates of marijuana use and the trend toward legalization of recreational
marijuana in the U.S., it is important to understand the chemicals within marijuana that are
known to contribute to the positive and negative health effects associated with using marijuana.
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Chemical Compounds in Marijuana
Marijuana contains over 400 chemicals (Lusk & Rutherford, 2017) and approximately
104 of these chemicals are cannabinoids (ElSohly and Gul, 2014). Cannabinoids are molecules
that can bind to cannabinoid receptors in cells (NASEM, 2017). There are two primary
cannabinoid receptors: 1) CB1 which is primarily expressed in the central nervous system
(Matsuda, Lolait, Brownstein, Young, & Bonner, 1990), and 2) CB2 which is primarily expressed
in the immune system (Galiègu et al., 1995). Research on marijuana has largely focused on
examining CB1 and CB2 receptors in response to two popular cannabinoids, Delta-9
Tetrahydrocannabinol (THC) and Cannabidiol (CBD).
Δ9 Tetrahydrocannabinol (THC). THC is the psychoactive compound within marijuana
that produces the intoxicating state often referred to as “feeling high”. This intoxicating state has
been described as “a pleasant euphoria and sense of relaxation” (National Institute on Drug
Abuse [NIDA], 2018). Furthermore, many individuals experience increases in appetite,
increases in laughter, heightened sensory perception (e.g., brighter colors), and altered
perceptions of time (NIDA, 2018). Importantly, the intoxicating state accompanying the
consumption of THC is not always pleasant. For example, some individuals report experiencing
heightened anxiety, panic, and fear; although the latter effects are more common when the
individual is inexperienced or has consumed large or unexpectedly high potency doses of
marijuana (NIDA, 2018).
Cannabidiol (CBD). CBD is a cannabinoid that is gaining a great deal of attention in the
last decade because it contains many of the same therapeutic properties of THC, however, does
not include the psychoactive components (Izzo, Borrelli, Capasso, Di Marzo, & Mechoulam,
2009). Thus, individuals can consume CBD as a treatment without the intoxicating side-effects.
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Research on CBD has proliferated for this reason. CBD contains the same chemical formula as
THC but has a minor difference in the atom arrangement (ElSohly and Gul, 2014). Scientists
believe that the differences in the atom arrangement prevents CBD from binding to the receptors
that THC binds to, making CBD non-psychoactive (ElSohly and Gul, 2014). Notably, THC and
CBD can be extracted from marijuana and used to create a number of products such as
tinctures/oils (e.g., liquid substance), topicals (e.g., lotions), and even edibles (e.g., “weed”
brownies).
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Methods of Consuming Marijuana
Smoking marijuana is the most common method of consumption. Marijuana is typically
inserted into a pipe (commonly referred to as a “bowl”) or rolled cigarette (commonly referred to
as a “joint”) and a flame is applied so that the marijuana combusts and releases smoke; the
smoke contains the active ingredients and is subsequently inhaled. Schauer and colleagues
(2016) examined a national sample (N = 4,269) of adults over the age of 18 and reported the
methods of consuming recreational marijuana in current users (as indexed by use in past 30 days)
was a pipe (49.5%); joint (49.2%); a bong, water pipe, or hookah (21.7%); a cigar wrap, referred
to as a blunt (20.3%); edibles/drinks (16.1%); and vaporizers (7.6%). See Table 2 for
explanations of the various methods of consuming marijuana.
Combusted vs. Ingested THC. Importantly, combusted (i.e., smoked) THC affects the
body differently than ingested THC. Specifically, the potency, onset, and duration of the effects
differs depending on the method in which marijuana is consumed (Carter, Weydt, KyashnaTocha, & Abrams, 2004; Ashton, 2001). For example, combusted THC is absorbed into the
pulmonary circulation and reverted from the pulmonary vein back to the heart (Benjamin &
Fossler, 2016). The combusted THC is subsequently distributed through the bloodstream
systematically, without passing through the liver (Benjamin & Fossler, 2016). Combusted THC
impacts the brain within seconds or minutes and thus psychoactive effects occur instantaneously
and typically last for one to three hours (Ashton, 2001).
In contrast, ingested THC is metabolized by the liver and converted into a chemical that
is much more psychoactive than delta-9 THC, referred to as 11-hydroxy-THC (Carter, Weydt,
Kyashna-Tocha, & Abrams, 2004). Ingested THC may take approximately 30 minutes to a
couple of hours before the psychoactive effects occur and the duration of psychoactive effects
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lasts longer (Ashton, 2001). Importantly, cannabinoids are extremely lipid soluble and thus they
accumulate in fatty tissues; the tissue elimination half-life of THC is approximately seven days
and the complete elimination of a dose could take up to 30 days (Ashton, 2001).
The various methods of consuming marijuana are important in the context of medicine
because each delivery method could serve a purpose contingent on the affliction that is being
treated. For example, combusted marijuana is the quickest method of delivery and could be used
to treat afflictions that need immediate relief (e.g., chronic pain, nausea, or spasms). Vaporizers
could alternatively be used if patients are not comfortable with smoking marijuana.
Additionally, edibles could be consumed if patients are not comfortable with smoking or vaping
marijuana, however, edibles may not be the best option for a patient experiencing nausea. Thus,
a tincture or topical created from THC or CBD oil is an alternative option for consuming
marijuana. CBD topicals (e.g., lotions) are another route of administration and can be applied
directly to localized areas of the body to relieve pain. It is important to note that manufactures of
marijuana edibles or topicals are not regulated by the Food and Drug Administration (FDA) and
safe levels of THC have not been established as of yet (Benjamin & Fossler, 2016). However,
restrictions have been created to regulate the content of THC within edibles at the state level in
marijuana-legalized states. For example, Colorado limited each “unit” of edible to a maximum
of 10 mg of THC and each package of edible products is limited to maximum of 100 mg of THC
(Parnes, Bravo, Conner, & Pearson, 2018). Although there are an abundance of marijuanaproducts being sold throughout the U.S., emerging research suggests that the dosage labels on
many of these products may be inaccurate (Bonn-Miller, Loflin, & Thomas, 2017; Vandrey et
al., 2015).
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Bonn-Miller, Loflin, and Thomas (2017) examined the accuracy of CBD extract labels by
purchasing 84 CBD products from 31 different companies on the internet. The authors reported
that approximately 70% of medical marijuana products sold online contained higher or lower
concentrations of CBD than the label indicated. Additionally, some of the products contained
significant amounts of THC (the psychoactive compound in marijuana), suggesting that a patient
consuming CBD could become unintentionally intoxicated. Of the 84 products purchased from
the internet, 42% of the products were under-labeled (containing a higher concentration of CBD
than indicated), 26% were over-labeled (containing a lower concentration of CBD than
indicated), and only 30% contained the specified CBD content (within 10%). Similar findings
were reported by Vandrey et al. (2015), who examined 75 different edible products (e.g., baked
goods, candy, or beverages) and found that 60% of the products were over-labeled (containing
lower concentrations of THC than indicated), 23% were under-labeled (containing higher
concentrations of THC than indicated), and only 17% were accurately labeled. There is great
variability in the labeling of non-FDA approved products however it is possible to have more
accurate labels as is the case with other meticulously controlled FDA approved cannabinoidbased products.
FDA Approved Drugs. Four drugs are currently licensed by the U.S. Food and Drug
Administration (FDA): 1) Dronabinol, is a synthetic analog of THC advertised under the name
Marinol® and is currently listed as a Schedule III drug (FDA, 2015); 2) Nabilone is a synthetic
analog of THC advertised under the name Cesamate® and is currently listed as a Schedule II
drug; 3) Syndros® is a liquid form of Dronabinol and is listed as a Schedule II drug; and 4)
Epidiolex® is the first FDA approved drug (approved in June, 2018) that contains natural
extracts of cannabis instead of human made synthetic variants. Notably, the first three drugs that
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were approved by the FDA were synthetic analogues of THC, referred to as cannabinoid receptor
agonists. Synthetic analogues of THC are a class of molecules created by chemists who take the
natural chemical composition of THC and slightly vary its chemical composition; thus, the
molecules still bind to cannabinoid receptors in a similar manner as THC or CBD.
Dronabinol (Marinol®) is administered orally and available through prescription in the
U.S. Specifically, Dronabinol is manufactured as a capsule containing synthetic THC in sesame
oil. Dronabinol was approved by the FDA in 1985 for the treatment of nausea and vomiting
associated with cancer chemotherapy. In 1992, the FDA approved marketing of Dronabinol for
the treatment of anorexia associated with weight loss in patients with AIDS.
Nabilone (Cesamate®) is also an oral capsule that was approved for marketing by the
FDA in 1985 and is prescribed to treat the same health afflictions as Dronabinol.
Syndros® is a liquid form of Dronabinol and is prescribed to patients experiencing
chemotherapy-induced nausea and vomiting when conventional antiemetic therapies are nonresponsive. Syndros® is prescribed for the treatment of anorexia associated with weight loss in
patients with AIDS.
Epidiolex® is a concentrated CBD oil containing over 98% CBD and is prescribed to
patients with two severe epileptic syndromes: Dravet and Lennox-Gastaut syndrome. Ironically,
considering that Epidiolex® is a natural extract of cannabis, it is still classified as a Schedule I
drug (declaring no medicinal benefits), despite research suggesting that Epidiolex® significantly
reduces drug-resistant seizures by 42% in epileptic patients (Devinsky et al., 2017).
Importantly, the FDA is currently examining another natural cannabis-based product
referred to as Nabiximols (Sativex®), an ethanol cannabis extract composed of a one-to-one ratio
of THC and CBD (gwpharm.com). Nabiximols was approved in the United Kingdom in 2010 as
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a prescription drug for mitigating multiple sclerosis-related spasticity, multiple sclerosis-related
bladder symptoms, neuropathic pain, and even sleep disturbance (gwpharm.com). Although
synthetic analogues of THC and extracts of THC or CBD are currently approved or further being
investigated by the FDA, another class of synthetic drugs that are not approved by the FDA have
emerged as a popular alternative to marijuana, referred to as ‘synthetic marijuana’.
Synthetic Analogues of Marijuana (Spice or K2). Synthetic marijuana (e.g., spice, K2) is
human made psychoactive chemicals that contain very potent activators of endocannabinoid
receptors and are sprayed onto dried plant material to mimic the effects of marijuana (Vardakou,
Pistos, & Spiliopoulou, 2010). These chemicals are referred to as cannabinomimetics, or
synthetic cannabinoid receptor agonists that mimic the effects of marijuana (Hudson et al.,
2010). Synthetic marijuana is commonly marketed by manufactures as “incense” or “herbal
blends” as an attempt to deceive consumers (NIDA, 2015; Zimmerman et al., 2009). Synthetic
marijuana is consumed by either smoking the dry plant material or vaping it in a liquid form
(Blundell, Dargan, & Wood, 2017). Synthetic marijuana users are likely to be individuals who
are seeking a cheaper alternative to marijuana or trying to pass a drug test (Drug Policy Alliance,
2016; Castellanos, Singh, Thornton, Avila, & Moreno, 2011). Synthetic marijuana is highly
toxic and has emerged as a public health concern in the last decade due to its association with a
number of adverse complications including seizures (Zhang, Patel, & Dani, 2018; Tait, Caldicott,
Mountain, Hill, & Lenton, 2016; Lapoint, James, Moran, Nelson, Hoffman, & Moran, 2011),
kidney failure (Zarifi & Vyas, 2017; Tait et al., 2016; Shanks, Dahn, & Terrell, 2012),
tachyarrhythmia (Lapoint et al., 2011), and mortality (Tait et., 2016; Shanks, Dahn, & Terrell,
2012). The incidences of individuals requiring medical attention due to having an adverse
reaction from synthetic marijuana has proliferated in the last decade.
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The U.S. Customs and Border protection first encountered synthetic marijuana such as
K2 and spice in 2008 (DEA, 2012). In 2009, 13 calls were made to U.S. poison control centers
across 41 states regarding synthetic marijuana over-doses (DEA, 2012). In 2010, nearly 600
calls were made to U.S. poison control centers in the first 6 months alone (Johnson, Johnson, &
Alfonzo, 2011) and consequently led to the Drug Enforcement Agency (DEA) introducing an
emergency ban on five cannabinomimetics (i.e. cannabicyclohexanol, CP 47,497, JWH 018,
JWH 073, and JWH 200) commonly found in synthetic marijuana. Despite having the ban in
place, approximately two thousand calls were made to the poison control in 2013 and almost
8,000 calls were made to the poison control in 2015 (Drug Policy Alliance, 2016).
Synthetic marijuana (e.g., spice) is currently classified as a Schedule I drug under the
Controlled Substance Act; nonetheless, synthetic marijuana is widely available online or at
smoke shops throughout the U.S. because manufacturers of synthetic marijuana circumvent
legislation by substituting banned cannabinomimetics with variants that are not yet prohibited
(Hudson et al., 2010). That is, the manufactures slightly alter the chemical composition of a
banned chemical and re-brand this newly created analog with a new marketing name. Notably,
the products available on the market change rapidly and have a life cycle of approximately 12-24
months before being replaced by newer product (Gurney, Scott, Kacinko, Presley, & Logan,
2014). This quick turnover further hinders efforts to schedule the drugs at federal and state levels
because newer products have emerged by the time the government bans older products.
Moreover, manufacturers proceed to bypass laws by including the words “Not safe for human
consumption” on the label of synthetic marijuana products. Overall, the innumerable problems
associated with synthetic marijuana suggest that synthetic marijuana products are truly not safe
for human consumption. In contrast, there is substantial evidence that many of the natural
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cannabinoids in marijuana are safe for human consumption and are effective for treating a
variety of health afflictions.
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Marijuana Therapeutic Effects and Health Consequences
Therapeutic Effects. The National Academies of Sciences, Engineering and Medicine
(NASEM) released a committee review in January 2018 examining the health effects of
cannabinoids and concluded that a number of afflictions can be treated with cannabis. The
NASEM (2017) committee categorized the weight of the evidence regarding cannabis or
cannabinoid use for health conditions into five categories: 1) conclusive evidence, 2) substantial
evidence, 3) moderate evidence, 4) limited evidence, and 5) no or insufficient evidence.

For

example, a therapeutic effect would be categorized as conclusive evidence only if there is strong
evidence from randomized control trials to support the conclusion. Notably, several major
findings emerged from the NASEM (2017) committee review. For example, the authors report
that there is “conclusive” or “substantial evidence” that marijuana is effective for treating the
following health afflictions: 1) marijuana is associated with significant reduction in chronic pain
symptoms, 2) oral cannabinoids are effective antiemetics for treating chemotherapy-induced
vomiting, and 3) oral cannabinoids are an effective treatment for multiple sclerosis spasticity
symptoms.
The authors of the current review created tables categorizing all of the therapeutic effects
reported in the NASEM (2017) committee review (see Tables 3 - 8). Additionally, we extended
upon the findings from NASEM (2017) by identifying studies reporting the therapeutic effects of
marijuana that have been published from 2016 to August 1, 2018 (see Table 9). A literature
review was conducted and the following databases were searched: PsycInfo, Medline, Google
Scholar, and Proquest Thesis and Dissertations. Reference sections within textbooks and peerreviewed articles were searched in order to identify additional sources. The following search
terms were used to identify articles: “cannabi*” and “marijuana.” In addition, the latter search
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terms were combined with the therapeutic effects and health consequences mentioned within the
NASEM review.
Several key findings emerged when examining recent research (see Table 9). For
example, a number of studies reported that marijuana was effective for treating chronic pain
(Park & Wu, 2017; Fanelli et al., 2017; Savage, Romero-Sandoval, Schatman, Wallace,
Fanciullo, McCarberg, & Ware, 2016; Boehnke, Litinas, & Clauw, 2016; Haroutounian et al.,
2016), chemotherapy-induced vomiting (Badowski, 2017), and seizures in epileptic patients
(Devinsky et al., 2018; Devinsky et al., 2017; Tzadok et al., 2016). Importantly, the NASEM
(2017) committee review concluded that there is “insufficient or no evidence” that cannabinoids
are associated with reductions in seizure activity in epileptic patients. Following this conclusion,
an Arizona physician named Dr. Sue Sisley was quoted saying that it was “unsurprising” that the
NASEM didn’t find evidence of cannabis being effective for epilepsy because there is a lack of
research due to marijuana’s classification as a Schedule I drug (Downs, 2017). Dr. Sisley went
on to state, “The federal government has systematically impeded efficacy studies,” implying that
it is extremely difficult to study the therapeutic effects of marijuana in a laboratory due to federal
research barriers (Downs, 2017).
Although NASEM concluded that there is “insufficient or no evidence” that cannabinoids
are associated with reductions in seizure activity in epileptic patients, we believe that the
evidence to oppose this conclusion is convincing. For example, Devinsky et al., (2017) found
that Epidiolex® significantly reduced drug-resistant seizures by 42% in epileptic patients.
Furthermore, Devinsky et al., (2018) found that CBD reduced the median number of seizures in
epileptic patients by approximately 51% in 12 weeks and 59% in 48 weeks. Striking evidence is
reported by Tzadok et al. (2016) who examined the efficacy of cannabis oil treatments in young
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children and adolescents (ages 1-18) that were diagnosed with epilepsy. Seventy-four patients
who were resistant to more than 7 antiepileptic drugs were recruited and treated for at least 3
months with cannabis oil. Nearly 9 out of 10 (89%) patients reported reductions in seizure
activity. Thirteen patients (17.57%) reported 75-100% reduction in seizure activity, 25 (33.78%)
patients reported a 50-75% reduction in seizure activity, nine (12.16%) patients reported a 2550% reduction in seizure activity, and 19 (25.68%) reported less than 25% reduction in seizure
activity. The latter findings demonstrate unequivocal evidence that marijuana was not only
effective, but also superior to many of the antiepileptic drugs currently on the market. Despite
this evidence, marijuana is still classified as a Schedule I drug and declared to have no medicinal
benefits. The evidence demonstrates the therapeutic effects associated with marijuana,
nevertheless, an important caveat to consider is that marijuana is also associated with a number
of health consequences.
Health Consequences. The health consequences associated with marijuana use were
synthesized in the NASEM (2017) committee review and weighted using the standardized
language provided in Table 3. Major findings reported within NASEM (2017) suggest that there
is substantial evidence indicating that the frequency of marijuana use is associated with: 1)
worsened respiratory symptoms and increases in bronchitis occurrences, 2) increases in the
development of schizophrenia and other psychoses, and 3) lower birthrates in offspring exposed
to marijuana while in the womb. The authors of the current review created tables categorizing
all of the health consequences reported in the NASEM (2017) review using their standardized
language to weight the evidence (see Table 10). Additionally, we extended upon the findings
from NASEM (2017) by identifying studies related to each health consequence associated with
marijuana that have been published from 2016 to August 1, 2018 (see Table 10).
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Importantly, NASEM (2017) highlighted the health consequences associated with
prenatal, perinatal, and neonatal exposure to marijuana, however, maternal outcomes associated
with using marijuana were only briefly discussed. Gunn et al. (2016) conducted a meta-analysis
examining maternal and child health outcomes associated with prenatal exposure to cannabis and
reported that anaemia is the “most widely discussed maternal outcome in cannabis-pregnancy
literature.” Specifically, the odds of women who used marijuana during pregnancy and
developed anaemia increased significantly (pooled OR = 1.36, 95% CI = 1.10 to 1.69) compared
to women who did not use marijuana during pregnancy. However, a caveat of the current
findings highlighted by the authors is that most research on marijuana users involves concurrent
users of tobacco and marijuana, thus ruling out a marijuana-only effect is often challenging
(Gunn et al., 2016). Considering this caveat, we found it important to highlight research
investigating the concurrent use of marijuana and tobacco; findings are presented later in this
review.
The NASEM (2017) committee review also highlights that there is moderate evidence
suggesting that marijuana use is associated with impairments in the cognitive domains of
learning, memory and attention. Additionally, the review reports that there is limited evidence
that marijuana use is associated with impaired academic achievement and educational outcomes.
Similarly, existing research suggests that adolescents who use marijuana demonstrate cognitive
disadvantages in comparison to adolescents who do not use marijuana (Jacobus & Tapert, 2014).
However, it is important to note that the conclusions of such existing research cannot imply
causation. That is, it is still unknown whether the observed cognitive disadvantages are
associated with pre-existing differences or if the observed cognitive disadvantages are associated
with using marijuana (Jacobus & Tapert, 2014). Findings that have been published since the
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NASEM (2017) review also suggest that the observed cognitive disadvantages in adolescents
may be associated with pre-existing differences instead of marijuana use (see Table 10).
Specifically, Meier et al., (2018) examined 1989 twins from the Environmental Risk (E-Risk)
Longitudinal Twin Study. The authors investigated the impact of the frequency of marijuana use
and marijuana dependence on neuropsychological decline as indexed by intelligence quotient
(IQ) scores. The authors found that twins who used marijuana more frequently than their cotwin did not score differently on 5-6 executive function tests (Ps > 0.10). The authors concluded
that short-term marijuana use in adolescents does not cause a decline in IQ scores or impair
executive functions. Notably, the authors explain that even when marijuana use reaches the level
of dependence, there is still not a decline in IQ or executive functions. The authors of the study
conclude that family background factors are the causal factor explaining why adolescent
marijuana users typically perform worse on IQ or executive function tests than non-users.
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Marijuana and Tobacco.
Concurrent Use of Marijuana and Tobacco. Over the past 5 decades the rates of tobacco
use have decreased significantly (Centers for Disease Control and Prevention [CDC], 2016)
however, the rates of concurrently using marijuana and tobacco are increasing. Schauer et al.
(2015) examined the National Survey on Drug Use and Health (NSDUH) which includes data
collected from a nationally representative sample of adults from 2003-2012. The authors
assessed trends in overall co-use and examined demographic characteristics associated with couse. The results suggest that there was a significant increase in the co-use of marijuana and
tobacco among adults between 2003-2012. Specifically, marijuana use among tobacco users
increased from 14.2% to 17.8% (p < .001). In contrast, tobacco use among marijuana users
decreased from 74.3% to 69.6% (p < .001). The authors suggest that the increase in the co-use of
marijuana and tobacco is attributable to increases in the prevalence of marijuana use among
tobacco users. Furthermore, the authors suggest that increases in access to marijuana through
legalization may subsequently contribute to the use of marijuana in tobacco users.
Similar findings were reported by Keyes et al. (2016) who analyzed data from the
Monitoring the Future (MTF) survey, a nationally representative survey of high school students
in the U.S. Keyes et al. (2016) examined the relationships between cigarette use and subsequent
marijuana use among cohorts of 8th, 10th and 12th graders. Findings suggest that lifetime
cigarette smoking in 8th and 10th grade was significantly associated with lifetime marijuana use
(β = 1.35, 95% CI: 0.52, 2.18) in 12th grade. Thus, 8th graders who reported having used tobacco
in their lifetime were more likely to report having used marijuana by the time they reached 12th
grade. Many researchers have aimed to investigate why individuals co-use marijuana and
tobacco. Although researchers have assessed reasons for co-use anecdotally by asking users to
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self-report why they use both substances, recent studies have investigated the chemicals within
each substance in order to determine if there are synergistic or additive effects that may be
unconsciously contributing to co-use.
THC and Nicotine Combined. Nicotine is the primary reinforcing chemical in tobacco
associated with addiction (National Institute on Drug Abuse [NIDA], 2012). Research suggests
that THC and nicotine may interact synergistically. For example, findings from animal model
research suggests that nicotine increases the rewarding effects of THC (Valjent, Mitchell,
Besson, Caboche, & Maldonado, 2002) and subsequently may contribute to increased
dependence on one or both substances (Ford, Vu, & Anthony, 2002; Peters, Budney, & Carroll,
2012; Ream, Benoit, Johnson, & Dunlap, 2008). In a study by Valjent et al. (2002), mice were
given doses of THC alone, nicotine alone, or co-administered each substance twice a day, over a
period of five days. Mice that were given both THC and nicotine experienced the acute
depressant effects induced by THC (i.e., avoidance response, locomotor activity, heart rate, body
temperature), and the effects were potentiated by nicotine. Additionally, rats co-treated with
THC and nicotine experienced altered levels of fear, withdrawal, and tolerance behaviors. The
latter results suggest that functional-biochemical interactions may be occurring after THC and
nicotine exposure. The authors of the study concluded that a synergistic interaction between
cannabinoid and nicotine receptor/neurotransmitter systems exists. Thus, the acute depressant
effects induced by THC were potentiated by nicotine co-administration. Furthermore, the
authors state that THC and nicotine co-administration could potentially be activating the
endogenous dopaminergic and opioid systems, leading to decreases in tolerance and higher
expression of THC physical dependence (Valjent et al. 2002).
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Similar findings also suggest that marijuana and tobacco interact synergistically when
consumed simultaneously. For example, González, Cascio, Fernández-Ruiz, Fezza, Di Marzo, &
Ramos (2002) reported that endocannabinoid levels in the brain are altered when rats are
provided chronic nicotine treatment. In contrast, there is pharmacological evidence suggesting
that cannabinoids alter nicotinic-acetylcholinergic receptor responses in the brain (Oz,
Tchugunova & Dinc, 2004). Anecdotal evidence reported from co-users of marijuana and
tobacco was highlighted in a review by Kohut (2017) that examined the interactions between
nicotine and drugs of abuse. Specifically, Kohut (2017) examined qualitative data suggesting
that marijuana users tend to report smoking tobacco after smoking marijuana because tobacco
enhances the effects of marijuana. These findings are supported in studies demonstrating that
mice intoxicated by THC self-administer more nicotine (Valjent et al., 2002). Additionally, in a
double-blind cross-over experiment by Penetar et al. (2005), ten male and ten female human
subjects were given either a placebo or a 21 mg transdermal nicotine patch 4 hours before
smoking marijuana. Significantly altered physiological (e.g., increased heart rate) and subjective
effects (e.g., subjects self-reported that the effects of THC lasted longer) were identified in
participants who were administered the nicotine patch in comparison to those who were
administered the placebo. Although research suggests that nicotine may increase the rewarding
effects of THC and thus may contribute to increased dependence on one or both substances, little
is known about the chemicals in the smoke emitted from marijuana and tobacco that may
contribute to the health consequences of co-use.
Mainstream (i.e., firsthand) and sidestream (i.e., secondhand) smoke. More than 480,000
deaths per year in the U.S. are attributable to tobacco use (US Department of Health and Human
Services, 2014) and the American Lung Association estimates that secondhand tobacco smoke
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causes approximately 7,330 lung cancer deaths among non-smokers per year (American Lung
Association, 2016). Intuitively, one would expect that similar consequences would emerge as a
result of smoking marijuana because marijuana smoke is emitted from burnt plant material and
the smoke is typically unfiltered (e.g., smoked in a joint or pipe). Moir et al. (2008) compared
the chemicals found in both mainstream (i.e., firsthand) and sidestream (i.e., secondhand) smoke
of marijuana and tobacco. The authors assessed the smoke composition and identified
carcinogens emitted from each substance. Moir et al. (2008) reported that nitrogen oxide,
hydrogen cyanide, and aromatic amines (such as 1-aminonaphthalene and 4-aminobiphenyl)
were present at levels of 3-5 times higher in marijuana mainstream smoke than tobacco smoke.
Ammonia was approximately 20 times higher in marijuana smoke compared to tobacco smoke.
Moreover, mainstream marijuana smoked contained lower concentrations of selected polycyclic
aromatic hydrocarbons (PAHs) in comparison to mainstream tobacco smoke. In contrast,
sidestream marijuana smoke contained higher concentrations of PAHs in comparison to
sidestream tobacco smoke. Moir et al. (2008) concluded that marijuana contains many of the
known carcinogens and other chemicals implicated in the respiratory diseases associated with
tobacco use. Thus, it is imperative to understand the negative impacts that secondhand
marijuana smoke may have on non-smokers. Research suggests that passive exposure to
marijuana smoke may result in testing positive for marijuana in a drug screening (Cone et al.,
1987; Moore et al., 2011).
Cone et al. (1987) sought to assess THC levels in the urine of individuals who were
passively exposed to marijuana smoke. The authors conducted a series of studies in seven
participants, five of which had a history of marijuana use but were abstinent for the past 14 days.
The other two participants did not have a history of marijuana use. In study one, the five
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participants with the history of marijuana use were exposed to a one-hour session in which a
cigarette-smoking manifold machine generated the side-stream smoke of 16 marijuana cigarettes.
In study two, the same five participants were exposed to a one-hour session in which a cigarettesmoking manifold machine generated the side-stream smoke of four marijuana cigarettes. In
study three, two participants were exposed to a one-hour session in which a cigarette-smoking
manifold machine generated the side-stream smoke of 16 marijuana cigarettes. Importantly,
passive smoke exposure was conducted in an unventilated room and room air levels of THC
were assessed frequently. The results suggest that passive exposure to the 16 marijuana
cigarettes resulted in positive testing for THC in all of the subjects; exposure to the passive
smoke of 4 marijuana cigarettes yielded infrequent positive results with low concentrations of
THC detected. These findings suggest that passive exposure to marijuana can result in testing
positive for marijuana, however, detectability is inconsistent if the passive exposure is low.
Moore et al. (2011) also analyzed THC levels in participants who were passively exposed
to marijuana but in a less controlled environment. Specifically, participants attended a Dutch
coffee shop where marijuana use is legal under strict conditions. Passive exposure was assessed
using saliva samples that were collected before entering the coffee shop and at five additional
time points (20min, 40min, 1h, 2h, and 3h). A final sample was collected 12-24 hours after
leaving the coffee shop. The authors sought to assess at which time point THC levels were
present. Notably, THC was detected in all of the participants at each time point (20min, 40min,
1h, 2h, and 3h) after entering the coffee shop. Other cannabinoids such as CBD and THCCOOH were not detected. These findings suggest that false positives in oral fluid results are
possible following passive THC exposure.
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Despite research suggesting that combusted marijuana contains many of the same
carcinogens and other chemicals associated with respiratory diseases in tobacco smokers, not a
single study has linked marijuana with tobacco related cancers such as lung cancer, colon cancer,
or rectal cancer (Hashibe et al., 2006; Tashkin, 2005; Melamede, 2005; Sidney, Beck, Tekawa,
Quesenberry, & Friedman, 1997). In fact, research has demonstrated that a number of the
constituents within marijuana may have anti-tumoral effects that inhibit the growth of a variety
of cancers such as lung cancer (Munson, Harris, Friedman, Dewey, & Carchman, 1975), skin
cancer (Casanova et al., 2003), breast and prostate cancer (Sánchez et al., 2001), leukemia and
lymphoma (McKallip et al., 2002), glioma (Sánchez, Galve-Roperh, Canova, Brachet, &
Guzmán, 1998), and pheochromocytoma (Sarker, Obara, Nakata, Kitajima, & Maruyama, 2000).
The latter findings suggest that the constituents within marijuana (e.g., THC) may counteract the
tumorigenic effects of the procarcinogens in marijuana smoke. Furthermore, the lung function of
5115 young adults over the course of approximately 20 years (beginning from age 18 to 30) was
assessed in a study published in the Journal of the American Medical Association examining risk
factors for cardiovascular disease (Pletcher et al., 2012). The authors found that tobacco
smokers demonstrated a decrease in lung function over time, whereas marijuana smoke produced
“unexpected” positive effects. Specifically, low to moderate users of marijuana demonstrated
increased lung capacity compared to nonsmokers. The authors reported that it was difficult to
estimate the potential effects of regular marijuana use due to the sample having an insufficient
number of regular marijuana users. Overall, there is still a current debate within the research as
to whether the differential impacts of marijuana and tobacco on the lungs are truly due to
marijuana having anti-tumoral properties or due to the variations in dosage. That is, the majority
of cigarette smokers tend to smoke multiple times daily, whereas, the majority of marijuana users
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tend to smoke a few times a month. In order to draw accurate conclusions regarding the health
consequences associated with combusted marijuana, further research needs to be conducted
examining heavy marijuana users who do not use tobacco.
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Marijuana Legislation Repercussions
The legalization of marijuana has resulted in a number of unexpected outcomes. For
example, reductions in opioid related deaths have been reported in states with liberal marijuana
laws (Livingston, Barnett, Delcher, & Wagenaar, 2017; Powell, Pacula, and Jacobson, 2015;
Hayes & Brown, 2014), reductions in prescription drugs for which marijuana could serve as a
clinical alternative have been documented in states that have legalized medicinal marijuana
(Bradford & Bradford, 2017), reductions in crimes such as homicide and assault have been
reported in states that have legalized recreational marijuana (Morris et al., 2011), increases in
fatal motor vehicle accidents involving marijuana-positive drivers have been reported in
Colorado (Salomonsen-Sautel et al., 2014). Counterintuitively, recent evidence suggests that
traffic fatalities decreased by approximately 10% in Nevada within the first year of legalizing
recreational marijuana (Margiott, 2018).
Marijuana Legislation and Opioids. A national crisis currently exists in the U.S. due to
opioid addiction or misuse. According to the National Institute on Drug Abuse (NIDA) more
than 115 fatal over-doses occur daily in the U.S. (NIDA, 2018). Heroin is one of the most
common contributors of fatal opioid related over-doses; however, prescription painkillers are
also addicting and often misused. Powell, Pacula, and Jacobson (2015) compared states that
have legalized medical marijuana with states that have not legalized medical marijuana. The
authors reported that states that have legalized marijuana have also experienced decreases in both
opioid addictions and opioid overdose deaths compared to states that have not legalized medical
marijuana. Similarly, Shi (2017) examined state-level annual administrative records of hospital
discharges during 1997–2014 and reported that medical marijuana legalization was associated
with 23% (p = 0.008) and 13% (p = 0.025) reductions in hospitalizations related to opioid
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dependence/abuse and the prevalence of opioid pain reliever overdoses. Monte, Zane, & Heard
(2015) suggest that marijuana is a safe clinical alternative for opioids because it may help with
pain control. Other studies have reported that CBD reduces the rewarding effects of morphine
(Katsidoni, Anagnostou, & Panagis, 2013) and CBD reduces cue-induced heroin seeking in
animal models (Ren, Whittard, Higuera-Matas, Morris, & Hurd, 2009). In sum, these findings
suggest that marijuana may serve therapeutic value as a treatment for pain relief, opioid
addiction, and substance abuse.
Effect on Doctors Prescriptions. Another repercussion following marijuana legalization
is a decrease in prescription drugs that marijuana could serve as a clinical alternative.
Specifically, Bradford and Bradford (2017) examined the prescriptions filled by Medicare Part D
enrollees from 2010 to 2013 and focused on prescriptions for health afflictions that marijuana
could serve as a clinical alternative. Medicare Part D is also referred to as the Medicare
Prescription Drug Benefit Program and was developed to help beneficiaries pay for prescription
drugs (Medicare, 2018). Notably, after medical marijuana laws were implemented, there was a
national overall reduction in Medicare program and enrollee spending estimated to be $165.2
million per year in 2013. The authors of the study concluded that the legalization of marijuana
significantly impacts prescription patterns and spending in Medicare Part D. Bradford and
Bradford (2017) reported that prescriptions for painkillers written by doctors reduced by
approximately 1,826 fewer doses (on average) per year after legalizing marijuana.
Marijuana Legislation and Crime. Findings related to the impact of marijuana
legalization on crime have yielded conflicting results. Some research suggests that marijuana
legalization may result in reductions in crime in areas that have legalized marijuana whereas
other research suggests that legalization increases marijuana-related crimes (e.g., carrying
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marijuana without a prescription). Morris et al. (2011) examined the relationship between
medicinal marijuana laws and crime across the United States. Crime data from each state was
gathered from the FBI’s Uniform Crime Reporting Program. The crime data included Part 1
offenses such as homicide, rape, robbery, assault, burglary, larceny, and auto theft. The authors
reported that medicinal marijuana laws were negatively associated with crime. Specifically, a
crime reduction of 2.4% was observed in reference to homicide and assault. Non-significant
findings were observed when examining robbery and burglary crimes. These findings suggest
that medicinal marijuana laws may be negatively associated with certain types of crimes.
Freisthler et al. (2017) examined the relationship between marijuana density outlets and
crimes in Denver, Colorado, during the time in which marijuana outlets were beginning to sell
for recreational purposes. The authors analyzed 481 census block groups over the course of 34
months (Jan. 2013-Oct. 2015); January 2014 was the year when marijuana began being sold for
recreational use. Three types of crimes were examined: 1) violence, 2) property, and 3)
marijuana-specific crime (i.e. crime committed against the retailer). The density of marijuana
outlets was not related to rates of violent crimes (murder, rape, robbery, and aggravated assaults)
and the density of marijuana outlets within the census block was not related to property crimes
rates. However, the density of marijuana outlets in spatially adjacent block groups was
positively correlated to property crime. For marijuana specific-crime, higher densities of
marijuana outlets within the census block and adjacent blocks was related to higher rates or
marijuana-specific crime. These findings suggest that the effects of the proximity of marijuana
outlets on crime do not occur within the block of marijuana retailers, but in adjacent areas.
However, marijuana-specific crimes are associated with the proximity of marijuana outlets.
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Another crime that is likely to increase as more states begin legalizing marijuana is Driving
Under the Influence (DUI) of a controlled substance (i.e., marijuana).
Motor Vehicle Accidents. Motor vehicle crashes are the leading cause of death each year
among young people ages 16- 25 in the United States (Azofeifa, Mattson, & Lyerla, 2015). The
most frequently detected substances in fatal car crashes in the U.S. are alcohol (National
Highway Traffic Safety Administration [NHTSA], 2013) and marijuana (Brady & Li, 2012). A
number of studies suggest that marijuana use within a month of driving a motor vehicle is
associated with two to six times higher risk of being involved in a motor-vehicle crash compared
to unimpaired drivers (Asbridge, Hayden, & Cartwright, 2012; Li et al., 2012; Baldock, 2008;
Beirness, Simpson, & Williams 2006; Ramaekers, Berhaus, van Laar, & Drummer, 2004; Bates
& Blakely, 1999). Research examining the impact of marijuana legalization on motor vehicle
accidents has yielded conflicting results. For example, Salomonsen-Sautel and colleagues
(2014) examined the proportion of fatal motor vehicle accidents before and after legalizing
marijuana in Colorado that involved alcohol-impaired (greater than the legal limit of 0.08 Blood
Alcohol Content [BAC]) and marijuana-positive drivers. The results suggest that after legalizing
marijuana in Colorado there was an increase in fatal motor vehicle accidents involving
marijuana-positive drivers (p <.0001); there was no difference in the proportion of motor
vehicle accidents involving marijuana-positive drivers in states that did not legalize marijuana.
In contrast, recent data suggests that traffic fatalities have decreased by approximately 10% in
Nevada in the first year of legalizing recreational marijuana (Margiott, 2018).
Notably, the impact of marijuana on driving performance is thoroughly documented
within the literature. Driving under the influence of marijuana is associated with decreases in
mean driving speeds, increases in weaving (within lanes), and increases in average distances
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headway to preceding vehicles (Hartman & Huestis, 2013; Downey et al., 2013; Bondallaz et al.,
2016; Anderson et al., 2010). However, it is important to note that a review by Sewell, Poling,
and Sofuoglu (2009) found marijuana use only had “modest” impairments on actual road tests.
The authors also reported that experienced marijuana users demonstrated “almost no functional
impairment” under the influence of marijuana “except when it is combined with alcohol.” The
latter effects are explained in a number of studies, highlighting that drivers under the influence of
alcohol tend to underestimate their degree of impairment; thus, they drive faster, increase
attempts to overtake vehicles, and decrease their average distance headway to preceding vehicles
(Robbe & O’Hanlon, 1993; Smiley, 1999; Sewell et al., 2009; Neavyn, Blohm, Babu, & Bird,
2014; Hartman & Huestis, 2013). In contrast, drivers under the influence of marijuana tend to
overestimate their degree of impairment; thus, they driver slower, make fewer attempts to
overtake, and increase their average distance headway to preceding vehicles (Robbe &
O’Hanlon, 1993; Smiley, 1999; Sewell et al., 2009; Neavyn et al., 2014; Hartman & Huestis,
2013). Research suggests that alcohol and marijuana consumed independently at low doses does
not yield sufficient driving impairments to rise to the level of a public health or safety concern,
however, driving performance is dramatically impaired when low doses of the two substances
are consumed simultaneously (Ramaekers, Robbe, & O'Hanlon, 2000; Hartman & Huestis, 2013;
Sewell et al., 2009).
Ramaekers et al., (2000) recruited eighteen participants and had them consume either an
alcohol placebo or a dose of alcohol designed to reach a peak BAC of 0.06-0.07 g/dl.
Participants concurrently consumed either a low dose of marijuana (100 µg/kg dose of
marijuana), a high dose of marijuana (200 µg/kg), or a marijuana placebo. Participants were
accompanied by driving instructors while driving on the highway after consuming either the
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placebo or the marijuana and alcohol combinations. Vehicles were equipped with additional
driving controls so that the instructor could take control of the vehicle in case of an emergency.
Driving performance tests assessed the number of times that the driver swerved between lanes
and overall lane stability. Notably, driving performance was not impaired in the placebo and
drug conditions in which alcohol or marijuana were administered independently. Conversely,
driving performance was impaired significantly when both substances were simultaneously
consumed and observed impairments increased as marijuana dosage increased.
In a study by Downey et al. (2013), 80 recreational marijuana users were recruited to
participate in six double-blind counter-balanced experimental sessions that involved consuming
varying doses of marijuana and alcohol, and subsequently driving in a simulator that mimics a
natural driving environment. Participants in the study smoked marijuana cigarettes containing
either 0% THC (placebo), 1.8% THC, or 3% THC. In addition, participants consumed sufficient
alcohol to achieve 0% BAC (placebo), 0.03% BAC, or 0.05% BAC. The results suggest that the
combination of both alcohol and marijuana produced the most driving impairments within the
simulator.
Further research is needed in order to clarify conflicting findings related to the impact of
marijuana legalization on motor vehicle accidents. However, substantial evidence suggests that
marijuana combined with alcohol results in detrimental driving impairments. Drivers in the U.S.
are legally allowed to drive after consuming alcohol when their BAC is less than 0.08%. A
public health threat may arise when drivers mistakenly assume that driving under the influence
of small amounts of marijuana and alcohol in combination will not severely impair their driving.
This potential misunderstanding is likely to become a major public health concern as more states
legalize the recreational use of marijuana.
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Regional Impacts of Marijuana.
The Paso del Norte (PdN) region stretches across two countries and three states: El Paso
and Hudspeth Counties in Texas, Doña Ana, Luna, and Otero counties in New Mexico, and the
municipality of Cuidad Juárez, Chihuahua, México. The impact of marijuana in either one of
these states or countries will have consequences on the region. Currently, none of the
constituents of the PdN region have legalized recreational marijuana. However, the national
trend toward the legalization of marijuana may still impact non-legal marijuana states including
those in the PdN region. For example, Texas has not legalized recreational or medicinal
marijuana. However, in 2015, The Texas Compassion Use Act was enacted to allow patients
with intractable epilepsy to access low-THC cannabis (Texas Department of Public Safety,
2016). New Mexico became the twelfth state to allow medical cannabis with the Lynn and Erin
Compassionate Use Act in 2007 (New Mexico Department of Health, 2018). The purpose is to
allow the beneficial use of medical cannabis in a regulated system for alleviating symptoms
caused by debilitating medical conditions. Most recently, México’s congress in 2017 approved
medical marijuana use and its pharmaceutical derivatives (Secretaría de Gobernacion, 2017). La
Secretaría de Salud is responsible for the development and enforcement of public policies to
regulate the medical use and upon completion of this paper, no such plan has been finalized.
Appendix A includes the current laws on marijuana or marijuana derivatives impacting the PdN
region.
Texas and Border Region. The Texas School Survey of Drug and Alcohol Use (TSS)
assessed current use and attitudes about licit and illicit drugs in 49,069 students in grades 7-12
from districts across the state (Texas Department of State Health Services; DSHS, 2016). The
results suggest that marijuana remains the most widely used illicit drug among Texas youth, that
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is, approximately 20.8% students reported using marijuana in their lifetime and 12.2% reported
using marijuana in the past-month preceding the survey. Furthermore, 21.4% of youth in the
border region of Texas (the study included three districts in El Paso County) reported using
marijuana in their lifetime and 12.8% reported using marijuana in the past month. In regards to
frequency of marijuana use, 1.6% of the participants reported everyday use, 2.0% of the
participants reported several times a week, 2.6% of the participants reported several times a
month, 3.1% of the participants reported about once a month, and 3.3% of the participants
reported about once a year.
Reports for Region 10 of Texas (El Paso County included) from different law
enforcement agencies report that marijuana and methamphetamine are the most trafficked drugs
for this area. According to the West Texas High Intensity Drug Trafficking Areas (HIDTA),
marijuana is currently priced between $225-300 per pound in El Paso (Texas Prevention
Resource Center [TPRC], 2018). Furthermore, CBD advertisements are proliferating across
storefronts in El Paso. CBD is currently being sold as gummies (see image 1), e-liquids (see
image 2), and oils at convenience stores, smoke shops, supermarkets with an emphasis on
organic food, and even at pharmacies. Furthermore, a pharmacy in El Paso (Surecare Specialty
Pharmacy) is the first businesses in El Paso to begin producing its own line of over-the-counter
CBD products.
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Image 1: CBD Gummies purchased at 7Eleven Store
in El Paso, TX on July 23, 2018.

Image 2: CBD E-liquid purchased at vape
shop in El Paso, TX on July 17, 2018.

In 2014, there were a total of 30,088 solid pounds of marijuana seized in El Paso, TX
(TPRC, 2018). In 2015, there was approximately 21,543 solid pounds of marijuana seized in El
Paso, TX (Texas Prevention Resource Center Region 10, 2018). In 2016, there was
approximately 13,299 pounds of marijuana seized in El Paso, TX (TPRC, 2018). The latter
results may suggest that the amounts of marijuana seized in El Paso each year are decreasing.
El Paso County recently approved the First Chance Program, preventing individuals
from being arrested if they are caught with less than 4 ounces of marijuana and it is the first
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offence (Claster, 2017). Under the First Chance Program, individuals who are caught with less
than four ounces of marijuana will have the option to complete eight hours of community service
and pay a $100 fine. Importantly, if the first time offender does not complete the program within
60 days or declines the option to complete the program, they will be arrested. As of June 2018,
Aliviane Inc. Treatment Resources, were treating 144 adolescents for mainly marijuana misuse
(TPRC, 2018).
Individual employers have approved policies related to marijuana or illegal substance use
throughout the PdN region. Appendix B includes the policies related to marijuana or illegal
substance use for El Paso’s top employers (i.e. El Paso Independent School District, Fort Bliss,
The University of Texas at El Paso, and Ysleta Independent School District).
New Mexico Counties. The prevalence of marijuana use in New Mexico and surrounding
counties is very high. According to a 2015 survey of 15,624 New Mexican youth from grades 912, approximately 1 out of 4 students (24.4%, CI: 23% to 25.9%) reported using marijuana
within the 30 days preceding the survey (NM-IBIS, 2018). Furthermore, approximately 1 out of
5 (19.9%, CI: 17.1% to 23.1%) of youth in Doña Ana County (the county in closest proximity to
El Paso, TX) reported using marijuana within the 30 days preceding the survey (NM-IBIS,
2018). In Otero and Luna Counties, it was reported that 30.7% and 23.3% of youth used
marijuana in the past 30-days, respectively.
West Texas High Intensity Drug Trafficking Areas (HIDTA) reports as of 2018,
marijuana prices range between $240-300 per pound in Las Cruces, NM (TPRC, 2018).
According to the New Mexico Department of Health (2018), as of March 31, 2018, there were
50,954 active patients in the Medical Cannabis Program, purchasing an average amount of 31.78
units (one unit of usable cannabis consists of one gram of the dried leaves and flowers of the
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female cannabis plant, or 0.2 grams of THC for cannabis-derived products). At the same time
point, Doña Ana County had 3,945 patients, Otero County had 1,457 patients, and Luna County
299 patients enrolled in the program.
Cd. Juárez, Chihuahua, Mexico. In a study published in 2016, the marijuana use among
7th – 12th graders in the state of Chihuahua was reported at 11.9% lifetime use (Velazquez et al.,
2016). In Cd. Juárez, 12.3% of students in 5th – 12th grade reported using marijuana, which is
above that of the national rate (Fregoso et al., 2015).
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Conclusions
The current report is a comprehensive review of marijuana to include its history,
composition, methods of consumption, therapeutic effects and health consequences, legislation,
and the impact of marijuana in the Paso Del Norte region with author’s recommendations on
decategorization, further research, and additional education among healthcare professionals
regarding marijuana. Records indicate that marijuana has been used for medicinal purposes for
thousands of years. Marijuana contains over 400 chemicals and approximately 104 of these
chemicals are cannabinoids (ElSohly and Gul, 2014). There are numerous products created that
include cannabinoids (e.g., THC and CBD) with various forms of consumption (e.g., edibles,
topicals). Multiple studies support using marijuana or cannabis-based medications for
therapeutic effects, however, there are mixed opinions when addressing the health consequences.
Legalization in some states have resulted in treatment for substance abuse, reduction in
prescription medications, and mixed results on crime.
Arguably, tobacco and alcohol comprise no medicinal benefits and are associated with
high fatality rates due to addiction and use-related illnesses, yet each substance is legal to
consume at a given age (i.e., age ≥ 18 years; age ≥ 21 years; respectively). In contrast, marijuana
is not associated with high fatality rates due to addiction and use-related illnesses, yet marijuana
is illegal to consume in non-legal marijuana states. Furthermore, “no one has died from an
overdose of cannabis” (Sifferlin, 2017). A problem that is discussed in many states that have
legalized marijuana is that the arrests due to marijuana possession impact people’s lives
permanently. For example, more than 200,000 American students have lost federal financial aid
eligibility because of a drug conviction (e.g., possession of marijuana) (Drug Policy Alliance,
2018b). “Stop ruining people’s lives for marijuana” was the promise that was proposed in
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Proposition 64, the initiative that legalized recreational marijuana use in California in 2016
(Proposition 64, 2016). Moreover, a topic that is increasingly discussed relates to evidence that
has surfaced suggesting that there are disproportionate mass incarcerations of minority drug
offenders (Golub, Johnson, & Dunlap, 2007; Alexander, 2012). For example, smoking
marijuana in public view is the most common misdemeanor arrest in New York City and most of
the arrestees are either black or Hispanic (Golub, Johnson, & Dunlap, 2007). Notably, in
comparison to whites, the black and Hispanic arrestees were more likely to be detained prior to
an arraignment, convicted, and sentenced to jail (Golub, Johnson, & Dunlap, 2007). An article
published in the New York Times on May 13th, 2018 highlighted these findings with a headline
that read, “Surest Way to Face Marijuana Charges in New York: Be Black or Hispanic”
(Mueller, Gebeloff, & Chinoy, 2018).
Given the current scientific evidence regarding the therapeutic effects and health
consequences associated with marijuana use, the authors of the current review support the decategorization of marijuana as a Schedule I drug. We recommend the change to support
additional research and assessment of the impact that medicinal marijuana could have on
wellbeing and quality of life. In contrast, we believe that further research is needed to make a
decision regarding supporting or opposing the legalization of recreational marijuana. We
acknowledge that there is a problem related to the amount of incarcerations associated with
marijuana possession in states in which marijuana is not legal. The authors of the current review
suggest that discussions regarding the decriminalization of marijuana (e.g., reducing penalties
associated with the possession of small amounts of marijuana for personal use and removing a
permanent criminal record) are warranted while further research is conducted to properly
evaluate the benefits and consequences of legalizing medicinal and/or recreational marijuana.
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Considering the evidence regarding disproportionate mass incarcerations of minority drug
offenders, decriminalizing marijuana could have an impact on the Paso Del Norte region,
comprised of a Hispanic majority population (Healthy Paso Del Norte, 2018).
Overall, we conclude that medical marijuana could be an appropriate treatment for
illnesses that marijuana has been shown to produce positive outcomes, especially in cases in
which the patient is resistant to other treatments. In contrast, legalization of recreational
marijuana needs to be supported by strong policies and effective mechanisms to monitor use and
the social, economic, and health impact. Given the national trend toward the legalization of both
medicinal and recreational marijuana, we believe that health professionals will increasingly be
consulted by patients regarding the use of marijuana as a treatment. Thus, we advocate that there
is a need for formal education on marijuana within school curriculums so that health
professionals are prepared to address many of the questions and concerns associated with using
marijuana as a treatment. Moeller and Woods (2015) reported that pharmacy students receive
minimal “formal” education on marijuana. Specifically, the authors recruited 311 pharmacy
students to complete a survey assessing attitudes and knowledge about marijuana and its
associated therapeutic effects and health consequences. More than half (58%) of students
reported that they believed medical marijuana should be legalized in all states, however, the
majority of students did not feel comfortable answering consumer questions related to marijuana
including the efficacy, safety, and drug interactions associated with using marijuana. In addition,
the authors reported that there was low accuracy in responses for diseases and conditions that
medical marijuana could be prescribed to treat.
Many gaps in knowledge emerged while conducting this review. For example, future
research should investigate the fluctuations in CBD or THC content in extracts and edibles with
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aims of improving the accuracy of doses on product labels. These fluctuations in the content of
CBD or THC could lead to inaccurate estimates of proper dosing and unintentional intoxications.
Another gap in the literature is that research findings related to marijuana users includes subjects
who are poly-users (e.g., use tobacco and / or alcohol in addition to marijuana). Future studies
need to exclude poly-users in order to better understand “marijuana-only” effects. Additionally,
as more states begin to legalize marijuana, the number of adults who will drive after consuming
legal amounts of marijuana in combination with legal amounts of alcohol are likely to rise.
Future research needs to investigate methods for regulating driving under the influence of
marijuana and alcohol in combination, as research suggests that driving performance is
detrimentally impacted by the simultaneous use of each substance. Research is also warranted
on regional data to include marijuana use, marijuana legislation support, perceived risk of
marijuana, intentions to use, and intention to use if legalized. Lastly, it is important to analyze
and better understand the psycho-social and physical health, crime and legal ramifications, and
economic repercussions that marijuana legalization would have in the Paso del Norte region.
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Table 1.
31 U.S. jurisdictions with medical marijuana laws as of December 03, 2018.
Jurisdiction
Medical Marijuana Recreational Marijuana
Year Passed
Year Passed
1. Alaska

1998

2014

2. Arizona

2010

3. Arkansas

2016

4. California

1996

2016

5. Colorado

2000

2012

6. Connecticut

2012

7. Delaware

2011

8. Florida

2016

9. Hawaii

2000

10. Illinois

2013

11. Louisiana

2016

12. Maine

1999

13. Maryland

2014

14. Massachusetts

2012

15. Michigan

2008

16. Minnesota

2014

17. Missouri

2018

18. Montana

2004

2016

2016
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19. Nevada

2000

2016

20. New Hampshire

2013

21. New Jersey

2010

22. New Mexico

2007

23. New York

2014

24. North Dakota

2016

25.Ohio

2016

26. Oklahoma

2018

27. Oregon

1998

28. Pennsylvania

2016

29. Rhode Island

2006

30. Utah

2018

31. Vermont

2004

2018

32.Washington

1998

2012

Washington, DC

2010

2014

33.West Virginia

2017

2015

Note: The information presented was compiled from ProCon.org (2018).
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Table 2.
Various Methods of Consuming Marijuana
Brief Description

Product Description

Pipe: Glass, wood, or metal device that marijuana
Smoking marijuana is the most common can be inserted into and used to inhale smoke.
method of consumption.
Bong or bubbler: Glass or plastic device that
uses water-filtration to filter smoke prior to
Involves applying a flame to burn the dry entering the lungs.
leaves of marijuana and inhaling the
Dab: Concentrated oil that is extracted using a
smoke.
solvent such as butane or carbon dioxide. A flame
is applied to the oil and the smoke is inhaled.
Joint: Unfiltered cigarette filled with marijuana.
Blunt: Cigar filled with marijuana.
Vaporizing marijuana is an emerging
method of consuming marijuana and
involves heating dry cannabis leaves or
concentrated THC/CBD oil to a level
high enough to transmit the THC/CBD
without the full combustion that results in
smoke. Vaporizing marijuana has gained
popularity because it is believed to be a
healthier option for consuming marijuana
without emitting the carcinogens, tars,
and toxins from combusted smoke.

Desktop Vaporizer: Device that connects to an
electrical wall outlet and allows for the
temperature of the heating device to be adjusted
precisely.
Portable Vaporizer: A battery operated device
that allows for mobile use. THC /CBD oils can be
combined with flavors (e.g., cherry) to provide a
pleasant taste and aroma to the vapor that is
inhaled and exhaled. E-cigarettes are becoming
the most common portable vaporizer due to their
sleek size and discreet appearance.
Candy: Examples of THC/CBD infused candy
include lollipops, gummy bears, and chocolates.

Ingesting marijuana edibles involves
extracting THC/CBD from the dry leaves
of cannabis and creating a butter that can
be used for cooking or baking.

Ingesting marijuana beverages are
growing in popularity because they are
easier to uptake into the intestines and
have lower fat content than edibles (i.e.,
brownies).

Baked Goods: Common baked goods include
brownies, cookies, and cupcakes. However, it is
important to note that marijuana infused butter can
be used to cook/bake any food or snack that
includes butter as an ingredient.
Coffee, Hot Coco, Tea, Alcohol, Soda: Beverage
is infused with marijuana.
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Capsule: Cannabis extract of THC/CBD inserted
into a capsule to be consumed orally.
Other marijuana pharmacological
derivatives: capsules, spray, tinctures,
and topicals are designed to be absorbed
orally or through one’s skin.

Spray: Concentrated CBD cannabis extract that is
applied to specific area of body and absorbed
through one’s skin.
Tincture: Concentrated THC or CBD cannabis
extract that is applied to specific area of body and
absorbed through one’s skin.
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Table 3.
Conclusive or Substantial Evidence Provided by the National Academies of Sciences,
Engineering, and Medicine (2017) Committee
Cannabis or cannabinoids are effective for treating:
Chronic Pain:
Significant reduction in pain symptoms (cannabis)
Chemotherapy-induced vomiting:
Oral cannabinoids are effective antiemetics (oral cannabinoids)
Multiple Sclerosis Spasticity Symptoms:
Improves “patient-reported” spasticity symptoms (oral cannabinoids)
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Table 4.
Moderate Evidence of Effectiveness Provided by the National Academies of Sciences,
Engineering, and Medicine (2017) Committee
Cannabis or cannabinoids are effective for treating:
Sleeping Aid:
Improves short-term sleep outcomes associated with obstructive sleep apnea
syndrome, fibromyalgia, chronic pain, and multiple sclerosis (cannabinoids,
nabiximols1)
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Table 5.
Limited Evidence of Effectiveness Provided by the National Academies of Sciences,
Engineering, and Medicine (2017) Committee
Cannabis or cannabinoids are effective for treating:
HIV/AIDS:
Increases appetite and decreases weight loss associated with HIV/AIDS (cannabis
and oral cannabinoids)
Multiple Sclerosis Spasticity Symptoms:
Improves “clinician-measured” spasticity symptoms (oral cannabinoids)
Tourette Syndrome:
Improves symptoms associated with Tourette’s (e.g., reduction in tics) (THC
Capsules)
Social Anxiety Disorder (SAD):
Improves anxiety symptoms (cannabidiol)
Posttraumatic Stress Disorder (PTSD):
Improves global clinical state, general well-being, and reduces nightmares
(Naboline2)
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Table 6.
Limited Evidence of a Statistical Association Provided by the National Academies of Sciences,
Engineering, and Medicine (2017) Committee
Cannabis or cannabinoids are effective for treating:
Traumatic Brain Injury or Intracranial Hemorrhage:
Improves overall outcomes such as reduction in mortality or disability (Cannabis)
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Table 7.
Limited Evidence of Ineffectiveness Provided by the National Academies of Sciences,
Engineering, and Medicine (2017) Committee
Cannabis or cannabinoids are ineffective for treating:
Dementia:
Increases weight gain, decreases disturbed behavior, and decreases negative affect scores
(cannabinoids)
Glaucoma:
Improves intraocular pressure (cannabinoids)
Chronic Pain or Multiple Sclerosis Depressive Symptoms:
Reduces depressive symptoms (nabiximols, dronabinol, nabilone)
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Table 8.
Insufficient or No Evidence Provided by the National Academies of Sciences, Engineering, and
Medicine (2017) Committee
Cannabis or cannabinoids are effective for treating:
Cancers:
Anti-tumor effects (cannabinoids)
Cancer-Associated Anorexia Cachexia Syndrome and Anorexia Nervosa:
Increases in weight (cannabinoids)
Irritable Bowel Syndrome:
Improves gastric transit, small bowel transit, or colonic transit (dronabinol)
Epilepsy:
Reduction in seizure frequency (cannabinoids)
Spinal Cord Injury Spasticity in Paralyzed Patients:
Reduction in muscle spasticity (cannabinoids)
Amyotrophic Lateral Sclerosis:
Increases in appetite and sleep, decreases in cramps or fasciculations (involuntary muscle
twitches) (cannabinoids)
Huntington’s Disease:
Decreases in chorea (abnormal, involuntary movements), decline in cognitive abilities,
psychiatric impairment (oral cannabinoids)
Parkinson’s Disease or Levodopa-Induced Dyskinesia:
Improvements in dyskinesia (abnormal, involuntary movements), quality of life, sleep, or
pain (cannabinoids)
Dystonia:
Reduction in dystonia as indexed by the Burke-Fahn-Marsden dystonia scale (naboline or
dronabinol)
Addictive Substances:
Abstinence from addictive drugs including marijuana (cannabinoids)
Schizophrenia or Schizophreniform Psychosis Mental Health Outcomes:
(cannabidiol)
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Table 9.
Research Published After the NASEM (2017) Committee Review Regarding the Therapeutic
Effects of Marijuana
Affliction
Updated Research
Described in
National
Academies of
Sciences,
Engineering, and
Medicine (2017)
Chronic Pain:
A literature review by Park and Wu (2017) examined 25 articles that
assessed prevalence of medical marijuana use, reasons for using medical
marijuana, and the perceived effects of medical marijuana. The authors
concluded that the most commonly endorsed self-reported reason for
using medical marijuana was to mitigate pain.
Fanelli et al. in 2017 recruited 614 adults in Italy to assess the
effectiveness of cannabis to treat chronic pain from various diseases (e.g.
multiple sclerosis, cachexia and anorexia among AIDS and cancer
patients, glaucoma, Tourette syndrome, and certain types of epilepsy).
Participants were given various doses and strains of cannabis for the
treatment of chronic pain. The treatment was given alongside their
regular prescribed treatment and self-reported data was collected to
assess levels of pain. The authors concluded that cannabinoids appear to
be an effective and safe method for treating chronic pain.
Savage et al. in 2016 reviewed the clinical and policy literature related to
marijuana use for the treatment of pain. The article included information
for healthcare professionals on protocols for the use of marijuana with
their patients. The review concludes that there are promising results for
the use of marijuana for pain. This review is useful for researchers and
healthcare professionals as it highlights clinical practice and future
research.
Boehnke et al. in 2016 conducted a cross-sectional retrospective survey
of 244 medical marijuana patients with chronic pain who obtained
medical marijuana from a Michigan dispensary from November 2013 to
February 2015. The article found that marijuana use was associated with
lower opioid use, increased quality of life and fewer medication side
effects among chronic pain patients. The study reports that marijuana
use is effective for treating chronic pain, however, an important caveat to
consider relates to the potential synergistic effects of using marijuana
and opioids concurrently.
Haroutounian (2016) recruited 176 participants (≥ age18) that had
experienced chronic pain lasting at least 3 months and previous adverse
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effects from 2 different drug classes at full dosage. The objective of this
study was to determine long-term effects of medical marijuana on pain in
participants with treatment-resistant chronic pain. S-TOPS pain score
improved from 83.3 to 75.0 and pain symptom score improved in 65% of
participants. Findings suggests that cannabis treatment in mixed groups
of patients with treatment resistant chronic pain can result in better
quality of sleep, improved pain management, and a reduction of the use
of opioids.
ChemotherapyBadowski (2017) conducted a pub med search to identify articles related
Induced
to cannabinoids and the treatment of nausea due to chemotherapy. The
Vomiting:
purpose of this review was to provide a summary of the efficacy,
pharmokinetics, pharmodynamics and safety of cannabinoids for patients
with chemotherapy-induced vomiting. Oral cannabinoids improved
efficacy or had similar results as conventional antiemetics in treating
patients with chemotherapy induced vomiting. The authors concluded
that oral cannabinoids are effective at managing nausea and vomiting
that is induced from chemotherapy but can have adverse effects when
compared to medication normally used to treat similar symptoms (e.g.,
dizziness).
Multiple Sclerosis Gyang Hyland, Samkoff, and Goodman (2018) conducted a cross
Spasticity
sectional study among patients that had been diagnosed with multiple
Symptoms:
sclerosis (MS) and transverse myelitis (TM). Fourteen subjects were
recruited from the University of Rochester MS Center and thirteen of the
subjects reported that they have used medicinal marijuana and 62%
reported that they use marijuana daily. The objective of this study was to
determine the effectiveness of medical marijuana in the management of
symptoms of MS and TM. Approximately 77% of the sample reported
that medical marijuana improved their quality of life. Additionally, the
subjects that reported that marijuana improved their quality of life also
reported that marijuana was useful for managing symptoms and did not
cause any side effects. The authors concluded that medical marijuana
seems to play a significant role in managing symptoms from MS and TM
by reducing spastic pain and by reducing the need to take other
medications.
van Amerogen et al. (2017) conducted a two-phase study in patients with
multiple sclerosis (MS). The goal of this study was to determine the
effectiveness of THC in reducing spasticity in patients with MS.
Biomarkers were used to study secondary pharmodynamic effects and
efficacy of the treatments with THC. Immediately after administration of
THC, pain was reported to have been reduced significantly by patients.
The authors concluded that oral use of THC for reducing the pain in
spastic patients with MS seems to be efficacious and may play a role in
the treatment of MS altogether due to the stable pharmacokinetic profile
of THC.
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Sleeping Aid:
[Opposite effect]

HIV/AIDS:
[No effect]

Tourette
Syndrome:

Patti et al., (2016) recruited a MS patient population of 1615 subjects
from 30 MS centers across Italy who were taking the oromucosal spray,
Sativex®. The researchers aimed to describe the effectiveness and
adverse events of Sativex®. Researchers wanted to determine how
effective the spray would be for treatment-resistant multiple sclerosis
(MS). Adverse effects as a result of taking the spray were also recorded.
After one treatment month, 70.5% of the subjects reached a ≥ 20%
improvement (initial response, IR) and 28.2% of the subjects reached a ≥
30% improvement (clinically relevant response, CRR) with a mean NRS
score reduction of 22.6. Importantly, during the 6 months of treatment,
39.5% of the subjects discontinued treatment for a number of reasons
including lack of effectiveness or adverse events. The study concluded
that Sativex® could be considered a useful and safe option for patients
with MS that experience moderate to severe spasticity.
Conroy et al. (2016) recruited 98 participants and examined associations
between marijuana use and sleep patterns. The objective of this study
was to determine the difference in the effects marijuana has on sleep with
users that consume at different rates (daily vs. non-daily users). Quality
of sleep and sleep patterns of the participants were also investigated. The
authors assessed dependence for marijuana use over the 4 weeks
preceding the survey and smokers were categorized as either daily
smokers (smoke marijuana at least 6 days per week), non-daily smokers
(smoke marijuana at least once per month, up to 5 days per week), and
non-users (no marijuana use in the past month). Sleep disturbance was
reported at 55.1% in daily marijuana users, 34.5% in non-daily users, and
45% of non-users. This study also gathered the rates of clinical insomnia
in daily users (38.8%), non-daily users (10.3%), and non-users (20.0%).
Daily marijuana users were found to experience more sleep disturbances
than non-daily users. Non-daily users and non-users both had similar
measures. This study suggests that daily marijuana use may not improve
sleep. Studies with larger numbers of participants are warranted.
Sinha et al. (2017) conducted a cohort study with patients enrolled in
Johns Hopkins HIV Clinic. A total of 1377 participants that were
receiving anti-viral therapy were selected to participate in study. The
study focused on the relationship between marijuana use and HIV
treatment without alcohol or other drug use. The results suggest that
there is not a statistically significant relationship between marijuana use
and treatment outcomes. In addition, marijuana use frequency was not
associated with negative treatment outcomes.
Abi-Jaoude (2017) identified 19 patients with Tourette Syndrome (TS) at
a western Toronto clinic. Participants were included in the study if they
were diagnosed with TS and used marijuana regularly for 6 months or
longer. The goal of this study was to determine the effectiveness and
tolerability of marijuana treatments in adult patients with TS. All
participants in the study experienced significant symptom relief.
Importantly, 18 of the 19 participants described the results of using
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Social Anxiety
Disorder (SAD):
Posttraumatic
Stress Disorder
(PTSD):
Traumatic Brain
Injury or
Intracranial
Hemorrhage:
Dementia:
Glaucoma:
Chronic Pain or
Multiple Sclerosis
Depressive
Symptoms:
Cancers:

CancerAssociated
Anorexia
Cachexia
Syndrome and
Anorexia
Nervosa:
Irritable Bowel
Syndrome:
Epilepsy:

marijuana to treat TS as “much improved”. Tic scores also decreased by
60% in patients. The authors reported that marijuana was well tolerated
by participants and appears to be a good option for treating patients with
TS with tic associated symptoms. While success was found in treating
TS patients with marijuana, it is important to note patients continued to
take other medications concurrently.
No new studies identified using the mentioned search criteria.
No new studies identified using the mentioned search criteria.
No new studies identified using the mentioned search criteria.

No new studies identified using the mentioned search criteria.
No new studies identified using the mentioned search criteria.
No new studies identified using the mentioned search criteria.

Bogdanovic (2017) conducted a literature survey of medical and
scientific databases with a focus on cannabinoids in cancer treatment.
The aim of the review was to discuss and overview the most significant
findings concerning cannabinoids in potential cancer treatment. Through
cannabinoid receptor and non-receptor signaling pathways, cannabinoids
demonstrate specific cytotoxicity against tumor cells, while protecting
healthy tissue from apoptosis. Cannabinoids also display potent
anticancer activity against tumor xenografts, including tumors that
express high resistance to standard chemotherapeutics. These findings
suggest cannabinoids have the potential to aid in cancer treatment, more
specifically anti-tumor effects. While these findings are promising, it is
important to note that few clinical trials that study the effects of
cannabinoids on cancers in human patients have been conducted. Further
research on the subject are warranted.
No new studies identified using the mentioned search criteria.

No new studies identified using the mentioned search criteria.
Devinsky et al., (2018) conducted an open label trial with patients that
were 30 years of age or younger. The objective of the study was to
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determine the effects CBD (Epidiolex) treatment would have on patients
with epilepsy, CDKL5 deficiency disorder, Aicardi, Doose, and,
Dup15q. All of the patients in the study had a case of severe childhood–
onset epilepsy. The study included 55 patients of which 20 had CDKL5
disorder, 19 had Aicardi syndrome, 8 with Dup15q syndrome, and 8 with
Doose syndrome. Patients received 10 or more weeks of CBD treatment
as part of a prospective interventional study. All patients who used CBD
were found to have decreased seizure frequencies when compared to
baseline reports. At baseline, patients (n=46) were found to have a
seizure frequency rate of 59.4%. At week 12 of the study patients (n=35)
had a seizure frequency rate of 22.5% and at 48 weeks patients (n=27)
seizure frequency rates were at 23.3%. This study provides valuable data
and evidence of long-term efficacy of the treatment of epilepsy, CDKL5
deficiency disorder, Aicardi, Dup15q, and Doose syndromes with CBD
(Epidiolex). The study suggested that future research should aim at
including placebo- controlled randomized trials to further address
concerns for safety in using CBD to treat patients with epilepsy.
Rosenberg, Louik, Conway, Devinsky, and Friedman (2017) conducted a
study that included 48 patients between the ages of 1-30 years old that
reported to currently have or previously had intractable childhood onset
epilepsy. Patients also reported having 4 or more seizures with a motor
component per 4-week period. After enrollment into the study, patients
kept a daily diary over a 4-week period to generate a baseline report on
daily seizures. A quality of life in childhood epilepsy survey was also
included to assess multiple quality of life domains. The objective of the
study was to determine the potential seizure reducing properties of
Epidiolex, which is purified CBD. Monthly motor seizure frequency
was 27.5% at baseline, however, by the 12-week observation period of
the study the monthly motor seizure frequency reduced to 13.9%.
Quality of life survey scores also increased after the 12 weeks of
treatment. Specifically, survey scores were at 37.8% at baseline;
following the 12 weeks of treatment survey scores had improved to
45.7%. The results of this study suggest that the effects of CBD on
patients with epilepsy could extend further than just reducing seizure
frequencies and also improve the overall quality of life in these patients.
However, the authors suggest that further studies utilizing placebo
controlled, double-blind trials are needed to confirm this claim.
O’Connell, Gloss, and Devinsky (2017) conducted a literature review
examining the use of cannabinoids on patients with treatment-resistant
epilepsy. Open label studies and randomized control trials were included
within the review. The goal was to determine the safety and efficacy of
the drug Epidiolex for the treatment of seizures when compared to a
placebo. The authors reported that in a sample of 120 patients with
Dravet Syndrome who had been taking at least 3 anti-epileptic drugs
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were assessed. The baseline rates for median convulsive seizure
frequency was 13 per month. Sixty-one patients received Epidiolex 20
mg/kg per day and 59 received the placebo. After the 14-week
treatment period had concluded, researchers determined that the median
reduction of epileptic seizures was 39% in the Epidiolex group and 13%
in the placebo. Although CBD may be effective at reducing convulsive
seizures in patients with epilepsy, the safety and efficacy of THC when
used alone or with CBD is still undefined in children and adults with any
epilepsy syndrome. Randomized control trials are necessary to properly
determine the safety and efficacy of THC.
Devinsky et al., (2016) conducted an open label trial that involved
patients between the ages of 1-30 years of age who were diagnosed with
severe, intractable, childhood-onset, treatment resistant epilepsy. The
main objective of this study was to determine the safety and tolerability
of cannabidiol and its effects on the mean frequency of motor seizures at
12 weeks. Patients were given a dose of oral cannabidiol that ranged
from 2-5mg/kg per day. Dosage was up-titrated until the cannabidiol
could no longer be tolerated or until the dosage of 25 mg/kg or 50mg/kg
per day depending on the study site. At baseline the median monthly
frequency of motor seizures was 30.0 (IQR 11·0–96·0) and reduced to
15.8 (5·6–57·6) after 12 weeks of treatment. The median reduction in
monthly motor seizures was 36.5% (IQR 0–64·7). This study’s findings
suggest that cannabidiol reduces the frequency of seizures and may have
a safety profile good enough for its use in children and young adults that
have been diagnosed with treatment-resistant epilepsy. Further studies
that make use of randomized controlled trials of the use of cannabidiol
are warranted to further understand the safety profile and efficacy of its
use.

Spinal Cord
Injury Spasticity
in Paralyzed
Patients:

Tzadok et al., (2016) examined the efficacy of treatment with cannabis
oil to in young children and adolescents ages 1-18 that were diagnosed
with epilepsy. Seventy-four patients who were resistant to more than 7
antiepileptic drugs were recruited and treated for at least 3 months with
cannabis oil. Nearly 9 out of 10 (89%) patients reported reductions in
seizure activity. Thirteen patients (17.57%) reported 75-100% reduction
in seizure activity, 25 (33.78%) patients reported a 50-75% reduction in
seizure activity, nine (12.16%) patients reported a 25-50% reduction in
seizure activity, and 19 (25.68%) reported less than 25% reduction in
seizure activity. The authors suggest that cannabis oil is an effective
treatment against seizures for children with epilepsy and further studies
using cannabis oils are needed to replicate these findings.
No new studies identified using the mentioned search criteria.
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Amyotrophic
Lateral Sclerosis:
Huntington’s
Disease:

Parkinson’s
Disease or
LevodopaInduced
Dyskinesia:
Dystonia:
Addictive
Substances:
Schizophrenia or
Schizophreniform
Psychosis Mental
Health
Outcomes:
[No effect]

No new studies identified using the mentioned search criteria.
Saft (2018) studied 7 patients with Huntington’s disease (HD) with
significant chorea and dystonia. Chorea and dystonia subscores were
taken before and after the administration of cannabinoids to determine if
cannabinoids can help motor symptoms in patients with HD. Motor score
and dystonia subscore improved from 70.9 to 60.6 with a mean
difference of 10.3 and from 12.3 to 8.0 with a mean difference of 4.3.
Cannabinoids improved motor symptoms, provided patients with healthy
weight gain and reduced apathy and irritability in patients.
No new studies identified using the mentioned search criteria.

No new studies identified using the mentioned search criteria.
No new studies identified using the mentioned search criteria.

Boggs et al., (2018) used a randomized placebo controlled and a parallel
group who had a fixed dose of oral CBD. The researchers used 36 stale
antipsychotic-treated patients diagnosed with chronic schizophrenia and
compared the cognitive, symptomatic and side effects of CBD versus a
placebo in clinical trial. They used MATRICS Consensus Cognitive
Battery (MCCB) and the Positive and Negative Syndrome Scale
(PANSS) as measures for testing. CBD augmentation was not associated
with an improvement in MCCB or PANSS scores and CBD was well
tolerated without worsening of mood, suicidality, or movement side
effects. These findings in this study are important because in this
particular case CBD augmentations did not provide benefits or negative
consequences.
Note: Table adapted from the National Academies of Sciences, Engineering, and Medicine
(2017) report titled: “The health effects of cannabis and cannabinoids: The current state of
evidence and recommendations for research”.
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Table 10.
Summary of the Health Problems Associated with Smoking Marijuana According to NASEM (2017)
Substantial Evidence Moderate Evidence Limited Evidence No or Insufficient
Evidence
Cancer

Cardiometabolic
Risk

No statistical
association that
smoking marijuana
increases incidence
of lung cancer, or
head cancer and
neck cancers.

Non-seminomatype testicular
germ cell tumors.

Acute myocardial
infarction,
ischemic stroke or
subarachnoid
hemorrhage,

Esophageal cancer,
prostate cancer,
cervical cancer,
malignant gliomas,
non-Hodgkin
lymphoma, penile
cancer, anal cancer,
Kaposi’s sarcoma,
or bladder cancer

Updated Research
No new studies
identified using the
mentioned search
criteria.

Parental use and
risk of
development of
cancer in
offspring: acute
myeloid
leukemia/acute nonlymphoblastic
leukemia, acute
lympoblastic,
leukemia,
rhabdomyosarcoma,
astroctyma, or
neuroblastoma.
Myocardial
No new studies
infarction.
identified using the
mentioned search
criteria.
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Respiratory
Disease

Immunity

Worse respiratory
symptoms and
increased chronic
bronchitis episodes.

Improved airway
dynamics with acute
use, but not chronic
use; higher forced
vital capacity;
improvements in
respiratory
symptoms.

decreased risk of
metabolic
syndrome and
diabetes, increased
risk of prediabetes.
Chronic
obstructive
pulmonary disease
(COPD) when
controlled with
tobacco use.
Decrease in
production of
several
inflammatory
cytokines. No
statistical
association with
progression of
liver fibrosis or
hepatic disease in
viral Hepatitis C
patients.

Hospital admissions
for COPD; asthma
development or
exacerbation.

No new studies
identified using the
mentioned search
criteria.

Adverse immune
cell responses in
healthy individuals.
Adverse effects on
immune systems of
HIV patients.
Increase in oral
human papilloma
virus (HPV).

Keen et al. (2017)
gathered
individuals who
tested negative for
THC (n=70) and
individuals who
tested positive for
THC (n=25). All 95
of the participants
were African
American and
tested positive for
HIV. The
objectives of this
study was to
determine the
effects of marijuana
use with people that
tested positive for
HIV. Patients who
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Injury and
Death

Risk of motor vehicle
crash.

Prenatal,
Perinatal, and
Neonatal
Exposure

Lower birthrate in
offspring.

(Maternal
Outcomes
included)

Risk of overdose
injuries (i.e.,
respiratory distress)
in pediatric
populations.

Occupational
accidents or
injuries, death due
to overdose.
Pregnancy
complications or
admissions of
infant to neonatal
intensive care unit
(NICU).

Offspring
outcomes:
cognition/academic
achievement,
sudden infant death
syndrome, or later
substance use.

tested positive for
THC had higher
CD4+ and CD8+
lymphocyte counts
than those who did
not consume THC.
These findings
suggest that THC
does not reduce
immune function
measured by CD
count. This study
echoes the results
of other studies and
also suggests that
marijuana may
interfere with the
virus’ ability to
transfer from one
cell to the next.
No new studies
identified using the
mentioned search
criteria.
Gunn et al. (2016)
conducted a metaanalysis examining
maternal and child
health outcomes
associated with
prenatal exposure
to cannabis and
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reported that
anaemia is the
“most widely
discussed maternal
outcome in
cannabispregnancy
literature.”
Specifically, the
odds of women
who used
marijuana during
pregnancy and
developed anaemia
increased
significantly
(pooled OR = 1.36,
95% CI = 1.10 to
1.69) compared to
women who did not
use marijuana
during pregnancy.
An important
caveat highlighted
by the authors is
that most research
on marijuana users
involves concurrent
users of tobacco
and marijuana, thus
ruling out a
marijuana-only
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Psychosocial

effect is often
challenging.
Impairment in
Impaired academic Sustained
Meier, Caspi,
cognitive domains of achievement and
abstinence from
Danese, Fisher,
learning, memory,
education
using marijuana and Houts, Arseneault,
and attention.
outcomes;
impairments the
& Moffitt, (2018)
impaired social
following cognitive examined 1989
functioning;
domains: learning, twins from the
increased rates of
memory, and
Environmental Risk
unemployment or
attention.
(E-Risk)
low income.
Longitudinal Twin
Study.
Specifically, the
authors examined
the impact of
frequency of
marijuana use and
marijuana
dependence on
neuropsychological
decline as indexed
by intelligence
quotient (IQ)
scores. The authors
found that twin
who used
marijuana more
frequently than
their co-twin did
not score
differently on 5-6
executive function
tests (Ps > 0.10).
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The authors
concluded that
short-term
marijuana use in
adolescents does
not cause a decline
in IQ or impair
executive
functions. Notably,
the authors explain
that even when
marijuana use
reaches the level of
dependence, there
is still not a decline
in IQ or executive
functions. The
authors claim that
family background
factors are the
causal factor
explaining why
adolescent
marijuana users
typically perform
worse on IQ or
executive function
tests that non-users.
Hirst, Young,
Sodos, Wickham,
and Earleywine
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(2017) recruited 62
participants that
were chronic
cannabis users and
asked them to
complete a
neuropsychological
battery which
included the
California Verbal
Learning Test-II.
The objectives of
this study was to
determine if effort
had an effect on
frequency or age of
long term cannabis
use and
learning/memory
performance.
Participants who
used cannabis more
frequently than
others displayed
poorer effort
measured by the
world memory test.
This study’s
findings indicate
that effort is the
driving force
between the
frequency of
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Mental Health

Frequency of use
associated with
development of
schizophrenia or other
psychoses.

Increased suicidal
ideation, attempts,
and suicide
completion;
increased incidence
of social anxiety
disorder; slight
increased risk for the
development of
depressive disorders.
Individuals
diagnosed with
psychotic disorders
experience:
improved cognitive
performance.
Individuals
diagnosed with
bipolar disorder
experience:
increased mania and
hypomania
symptoms.

Increase in
symptoms of
anxiety; increase
in developing
bipolar disorder
and anxiety
disorders.

Changes depressive
disorder symptoms
or the development
of PTSD.

cannabis use and
performance on
learning and
memory measures.
No new studies
identified using the
mentioned search
criteria.

Individuals with
psychotic
disorders:
Increase in
positive symptoms
of schizophrenia.
Individuals with
posttraumatic
stress disorder
(PTSD)
Increased severity
of PTSD
symptoms.

Individuals with
psychotic
disorders: No
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Problem
Marijuana Use

Frequency of use is
associated with
developing
problematic
marijuana use.
Risk factors for
developing
problematic
marijuana use:
initiating marijuana
use at early age, being
a male cigarette user.
Attention deficit
hyperactivity disorder
(ADHD) being treated
with stimulants does
not result in
problematic cannabis
use.

statistical association
of worsening
negative symptoms
of schizophrenia.
History of
Childhood anxiety
psychiatric
and childhood
treatment; increased depression.
severity of PTSD
symptoms.
Risk factors for
developing
problematic
marijuana use:
being a male, having
major depressive
disorder, combined
use of abused drugs.
Risk factors for
developing
problematic
marijuana use in
adolescents:
Frequency of use,
poor school
performance,
antisocial behaviors,
childhood sexual
abuse, initiation of
alcohol at early age,
exposure of

Guttmannova et al.
(2017) recruited
808 participants
who regularly
consumed
marijuana during
adolescence and
young adulthood.
The objectives of
this study was to
explore the
relationship
between regular
marijuana use from
adolescence to
adulthood and its
effect on the mental
health of
participants at age
33. Regular
marijuana use from
adolescence to
adulthood was
positively
associated with
cannabis use
disorder, alcohol
use disorder, and
nicotine
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combined used of
abused drugs.

Abuse of Other
Substances

Not risk factors for
developing
problematic
marijuana use in
adolescents:
Adolescent ADHD;
anxiety, personality
disorders, and
bipolar disorders;
alcohol dependence;
nicotine dependence.
Development of
substance
dependence or
substance abuse
disorder for alcohol,
tobacco, and other
illicit drugs.

dependence at age
33.

Initiation of
tobacco use;
changes use
patterns of licit
and illicit
substances.

No new studies
identified using the
mentioned search
criteria.
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Appendix A
Law Descriptions in PdN Region
Mexico

New Mexico
th

Texas

Federal

Description

Congress approved medical
use marijuana and its
pharmaceutical derivatives.

New Mexico became 12
state to allow medical
cannabis with the Lynn and
Erin Compassionate Use Act.
The purpose is to allow the
beneficial use of medical
cannabis in a regulated
system for alleviating
symptoms caused by
debilitating medical
conditions (i.e., cancer,
glaucoma, multiple sclerosis,
damage to the nervous tissue
of the spinal cord, epilepsy,
HIV, admitted to hospice
care, & others approved by
the department of health)
and their medical treatments.

The Texas Compassionate
Use Act was enacted to allow
patients with intractable
epilepsy to access low-THC
cannabis. The bill required
the Texas Department of
Public Safety (DPS) to create
a secure registry of physicians
who treat epilepsy. DPS
licensed 3 dispensing
organizations that meet
requirements. The license
authorizes the organizations
to cultivate, process, and
dispense low THC cannabis to
prescribed patients.

The use, sale, and possession of all
forms of cannabis in the United
States is illegal under federal law. As
a Schedule I drug under the federal
Controlled Substances Act of 1970,
cannabis is considered to have “no
accepted medical use” and have a
high potential for abuse and physical
or psychological dependence.
Individual states have enacted
legislation permitting exemptions
mainly for medical and industry use.

Adoption Year
Bill

2017
Articulo 237

2007
Senate Bill 523

2015
Senate Bill 339

1970
Controlled Substances Act
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Requirements

Enrollment

Products that contain
derivatives of cannabis in
concentrations of 1% or less
of THC.

Ministry of Health (La
Secretaría de Salud) is
responsible for development
and enforcement of public
policies to regulate the
medical use. * as per website
– no updates due to federal
elections (July 2018)

A patient can apply by
completing an application.
Application includes:
patient’s information and
signature; signature from
provider with prescribing
authority certifying the
applicant has been diagnosed
with one of the qualifying
conditions. A valid New
Mexico ID.
A practitioner needs to be
licensed in NM to prescribe
and administer drugs that are
subject the Controlled
Substances Act.
Application is reviewed
medically and
administratively to ensure all
requirements are met.
Possession of no more than
230 units (~8 oz) over a 3
month period. The right to
purchase from a Licensed
Non-Profit Producer. The
right to posses any
paraphernalia in connection
with their use of medical
cannabis. If the patient is not
in possession of their card,
they shall be given time to
produce card before arrest or
criminal charges. The right to

Patient must be a permanent
resident of Texas, diagnosed
with intractable epilepsy,
qualified physician
determines medical use and
second qualified physician
concurs. Physician must
enroll in the Compassionate
Registry of Texas (CURT)
System. Dispensing
organization must be
approved by DPS.

The 3 dispensing organization
licenses are to Cansortium
Texas, Compassionate
Cultivation, and Surterra
Texas; DPS not accepting
applications for new
enrollees. Low-THC cannabis
is defined as marijuana that
contains 10% or more
cannabidiol (CBD) and not
more than 0.5%
tetrahydrocannabinol.
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apply for a personal
production licenses (PPL), to
allow enrollee to grow for
personal use. If approved,
patient can have up to 16
plans, 4 mature (flowering),
and 12 seedlings.
Criminal prosecution or civil
penalty for possession,
distribution, transfer, or use
of cannabis or a cannabisderived product (1) in a
school bus or public vehicle;
(2) on school grounds or
property; (3) in the workplace
of the qualified patient's or
primary caregiver's
employment; (4) at a public
park, recreation center,
youth center, or other public
place; (5) to a person not
approved by the department
pursuant to this rule; (6)
outside New Mexico or
attempts to obtain or
transport cannabis, or
cannabis-derived products
from outside New Mexico; or
(7)that exceeds the allotted
amount of usable medical
cannabis, or cannabis-derived
products.

Restrictions

La Secretería de Salud had
180 days from 04/28/2017

Once a prescription is
dispensed, the product will
be labeled with information
to assist law enforcement in
confirming the legitimacy of
the prescription and the
patient's legal right to
possess low-THC cannabis.

2009 Ogen memo and 2013 DA
General James Cole communicated
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Notes

Source(s)

(~12/12/2017) to study the
medicinal and therapeutic
effects of cannabis before
creating the framework for a
medical marijuana program
infrastructure.

http://www.dof.gob.mx/nota
_detalle.php?codigo=548733
5&fecha=19/06/2017

https://nmhealth.org/about/
mcp/svcs/info/

https://www.dps.texas.gov/R
SD/CUP/index.htm

state legal medical marijuana is not a
priority.
The 2014 Rohrabacher-Farr
amendment remains in effect to
protect state-legal medical cannabis
from enforcement of federal law.
The Agricultural Act of 2014 allows
for university and state-level
departments of agriculture to
cultivate cannabis for research into
its industrial potential.
January 4, 2018, U.S. Attorney
General Jeff Sessions issued a memo
instructing U.S. Attorneys to enforce
federal law related to marijuana.
Clarke, R. & Merlin, M. (2013).
Cannabis: Evolution and
Ethnobotany. University of California
Press p. 185. ISBN 978-0-520-954571.
Jump up. DEA (2013). The DEA
Position on Marijuana. Dea.gov.
Retrieved May 16, 2018.
https://www.justice.gov/opa/pr/justi
ce-department-issues-memomarijuana-enforcement
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Appendix B
El Paso Top Employer Policies
Top
Employer in
El Paso, TX
El Paso
Independent
School
District

Fort Bliss

Policy

Source

El Paso Independent School District is committed to maintaining an alcohol and
drug free environment and will not tolerate the use of alcohol and illegal drugs
in the workplace and at school-related or school-sanctioned activities on or off
school property. Employees who use or are under the influence of alcohol or
illegal drugs as defined by the Texas Controlled Substances Act during working
hours may be dismissed. The District’s policy regarding employee drug use can
be found online at www.episd.org. See policies DH (Local) and DI (Local) and
(Exhibit).

http://www.allenrhaynes.com/
uploads/2/1/8/6/21865464/epi
sd_employee_handbook__20140108.pdf

Policy Code: DHE(Local)
Policy Title: Employee Standards of Conduct Searches and Alcohol/Drug Testing
Action and Summary of Revisions: REVISE POLICY The enclosed revisions are
recommended to clarify when REASONABLE SUSPICION ALCOHOL OR DRUG
SCREENING is required for an employee. At DRUG-RELATED VIOLATIONS,
employees subject to the Department of Transportation testing program would
not be eligible for reinstatement if they are found to have a drug-related
violation.
Approved: YES
Federal law on marijuana remains unchanged. Marijuana is categorized as a
controlled substance under Schedule I of the Controlled Substance Act. Thus
knowing or intentional marijuana possession is illegal, even if an individual has
no intent to manufacture, distribute, or dispense marijuana. In addition,
Executive Order 12564, Drug-Free Federal Workplace, mandates that (a) Federal
employees are required to refrain from the use of illegal drugs; (b) the use of
illegal drugs by Federal employees, whether on or off duty, is contrary to the
efficiency of the service; and (c) persons who use illegal drugs are not suitable
for Federal employment. The Executive Order emphasizes, however, that

https://tools.episd.org/tools/in
line/file_manager/board/policy
_manual/MTYsNjcsMTYk0T_opI
A0gbqtLbd3oVrtLnUWoMNKI1ySd3Jx1dRJWMFdEYbRQx62QIpYvfruVY0hUf_ay1jH
vJ9RyyiLby30VFtRR31ShxgJkYAlg3CcYWvHIplR3
8x8wEI4972w0W0RA
https://chcoc.gov/content/fed
eral-laws-and-policiesprohibiting-marijuana-use
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Ysleta
Independent
School
District

discipline is not required for employees who voluntarily seek counseling or
rehabilitation and thereafter refrain from using illegal drugs.
Ysleta ISD is committed to maintaining an alcohol and drug-free environment
and will not tolerate the use of alcohol and/or illegal drugs in the workplace and
at school related or school-sanctioned activities on or off school property.
Employees who use or are under the influence of alcohol or illegal drugs as
defined by the Texas Controlled Substances Act during work hours may be
dismissed. The district’s policy regarding employee drug use is as follows:

https://www.yisd.net/cms/lib/
TX01917279/Centricity/Domain
/498/20172018%20Employee%20Handbo
ok.pdf

An employee shall not manufacture, distribute, dispense, possess, use, or be
under the influence of any of the following substances during or outside of usual
working hours:
Any controlled substance or dangerous drug defines by law including but not
limited to marijuana, any narcotic drug, hallucinogen, stimulant, depressant,
amphetamine, or barbiturate.

The
University of
Texas at El
Paso

EXCEPTIONS: Sn employee who manufactures, possesses, or dispenses a
substance listed above as part of the employee’s job responsibilities, or who
uses the drug authorized by a licensed physician prescribed for the employee’s
personal use shall not be considered to have violated this policy.
The unlawful purchase, manufacture, sale, distribution, possession, storage or
use of an illegal drug or controlled substance in or on any premises or property
owned or controlled by the University is prohibited.

https://admin.utep.edu/Defaul
t.aspx?tabid=30505

All persons who are applicants for or who are employed as Commissioned Police
Officers, in positions with duties or activities that require possession of a
commercial driver’s license, or in certain other safety-sensitive positions,
designated by the University, will be required to provide a urine sample for
testing for the presence of illegal drugs and/or alcohol.
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